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The transcription factor p53 is an important master regulator of the cellular response to 
stress. Mdm2 is an E3 ubiquitin ligase that is the primary negative regulator of p53. 
Mdm2 downregulates p53 activity through three mechanisms: proteasome-mediated 
degradation, exportation from the nucleus, and direct inhibition through binding. Though 
the roles of the Mdm2-p53 axis in cancer have been well characterized, the relationship 
between p53 and other diseases remain elusive. Recently, three novel Mdm2 mutations 
were identified in patients with premature aging. One mutation leads to the abolishment 
of the Mdm2 stop codon, thereby extending the Mdm2 C-terminus by five additional 
amino acids. The other mutation leads to alternative splicing of Mdm2, resulting in two 
isoforms: a full length Mdm2 protein with a point mutation in the p53 binding domain and 
a truncated Mdm2 protein that has a 25 amino acid deletion in the p53 binding domain. 
Our results indicate that the causative Mdm2 variants are hyper-stable and lead to 
increased p53 protein stabilization. The anti-terminating mutant Mdm2 is defective as an 
E3 ligase, but retains its ability to bind and dampen p53 activity. However, p53 can be 
hyper-activated upon induction. Analysis of patient fibroblasts, patient lymphoblastoid 
cell lines, and genome-edited cells that express mutant Mdm2 confirmed the aberrant 
regulation of p53. MdmX may also potentially play a compensatory role in this axis. 
Altogether, our results demonstrate that defective Mdm2 can lead to constitutive 
dysfunctional regulation of p53 and contribute to accelerated aging phenotypes. 
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 This dissertation is divided into five chapters. Chapter one is an introduction to p53, 
Mdm2, MdmX, and aging. Chapter two is a draft of a manuscript that has been 
submitted and is under revision. It discusses how an anti-terminating mutant in Mdm2 
can lead to dysfunctional activation of p53 and premature aging. Chapter three is an 
extension of the work and examines the role of MdmX in Mdm2-p53 signaling. Chapter 
four discusses two other aging-related Mdm2 variants that deregulate p53. Chapter five 
















Cumulative genomic damage can manifest at the cellular level in two ways: in 
cancer, cells gain fitness to proliferate rapidly and uncontrollably, while in aging, cells 
lose fitness and stop proliferating (Campisi, 2013; Hanahan et al., 2011; Lopez-Otin et 
al., 2013). In order to maintain cellular homeostasis and genomic integrity, stress 
response pathways are often activated. One critical protein that responds to 
endogenous and exogenous stressors is the tumor suppressor p53. p53 functions as a 
transcription factor to promote processes such as cell cycle arrest, senescence, 
apoptosis, and DNA damage repair (Levine, 1997; Vousden et al., 2009).  
 
Discovery of p53 
p53 was initially discovered in 1979 as a protein that binds to the tumor-
promoting product from the DNA tumor virus Simian Virus 40 (SV40) (Lane et al., 1979; 
Linzer et al., 1979). Early studies suggested that p53 could cooperate with ras 
oncogene to transform rat embryo fibroblasts (Eliyahu et al., 1984; Jenkins et al., 1984). 
However, cDNA of p53 in those experiments were revealed to contain an oncogenic 
mutation. By the late 1980s, p53 was confirmed as a key tumor suppressor when 
several groups demonstrated that wild type p53 could suppress transformation and 
inhibit the growth activities of SV40 large T-antigen (Eliyahu et al., 1989; Finlay et al., 
1989; Friedman et al., 1990). Furthermore, p53 mutations were found in a variety of 
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tumor types, emphasizing the tumor suppressive nature of the gene. (S. J. Baker et al., 
1989; Nigro et al., 1989; Vogelstein, 1990).  
 
p53 and tumor suppression 
Many lines of evidence exist to support the role of p53 in tumor suppression. 
Besides being the most commonly frequently mutated gene in cancer, p53 loss in 
cancers was consistent with the Knudson two-hit model. In addition, hereditary mutant 
p53 was implicated as the driving mutation in families with Li-Fraumeni syndrome who 
have high predisposition for cancer (Malkin et al., 1990; Srivastava et al., 1990). The 
generation of mice that lacked one or both alleles of p53 confirmed that p53 loss is 
associated with a greater cancer incidence rate (Donehower et al., 2009). In particular, 
homozygous p53-null mice developed normally, but are predisposed for more 
lymphomas and sarcomas (Donehower et al., 1992). Finally, tumor viruses such as 
HPV can target the p53 pathway through its viral E6 proteins (Scheffner et al., 1990; 
Werness et al., 1990).  
p53 became known as the “guardian of the genome” and its tumor suppression 
functions were soon identified (Lane, 1992). In response to stressors such as DNA 
damage and radiation, p53 is able to mediate a variety of cellular outcomes, including 
cell cycle arrest and apoptosis (el-Deiry et al., 1993; Lowe et al., 1993). p53 is also able 
to promote DNA repair, senescence, and autophagy. Recently, p53 has emerged to 
play roles in metabolism, stem cell exhaustion, and inhibition of metastasis (Bieging et 
al., 2014). In the past year, new studies have also implicated p53 in the regulation of 
ferroptosis, a form of iron-dependent cell death (Dixon et al., 2012; Jiang et al., 2015). 
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The p53 transcriptional program is modulated by multiple mechanisms, as discussed 
later: 1) p53 REs and the target gene promoter architecture, 2) p53 protein levels and 
stabilization, 3) stressors and stimuli, 4) post-translational modifications, and 5) protein 
binding. 
The frequent missense mutations in the p53 DNA binding domain suggest a 
potential gain of function role for mutant p53 in cancer development. In particular, six 
“hotspot” p53 mutations featuring two contact mutations (248 and 273) and four 
structural mutations (175, 245, 249, 282) are able to disrupt p53-DNA binding and 
transactivation (Freed-Pastor & Prives, 2012). In addition to a dominant-negative effect 
on p53 by the generation of mixed tetramers, mutant p53 may drive further cellular 
malignancy and aggressiveness (Brosh et al., 2009). In our lab, mutant p53 has been 
linked to mevalonate pathway and VEGFR2 dysregulation in breast cancer (Freed-
Pastor, Mizuno, et al., 2012; Pfister et al., 2015). Knock-in mouse models further 
confirm the pathogenicity of such gain of function activities, as p53 mutant mice display 
shorter tumor latency and increased metastatic potential in comparison to p53 null mice 
(Donehower et al., 2009; Hanel et al., 2013; Heinlein et al., 2008; Olive et al., 2004). 
p63 and p73 are two structural homologs belonging in the p53 family of proteins 
(Kaghad et al., 1997; Schmale et al., 1997; A. Yang et al., 1998). Both proteins have 
two categories of isoforms: TA isoforms that have transactivation domains, and N 
isoforms that lack N-terminal domains (Su et al., 2013). TAp63 and TAp73 isoforms 
have transcriptional activity and tumor suppressor functions that are synergistic with p53 
activity (Guo et al., 2009; Su et al., 2010; Tomasini et al., 2008). In contrast, Np63 and 
Np73 have oncogenic properties through inhibiting p53/TAp63/TAp73 transactivation. 
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Overexpression of tumor-derived mutant p53 can directly bind to p63 and p73 to inhibit 
p63 and p73 transcriptional activity and promote tumorigenesis (Di Como et al., 1999; 
Gaiddon et al., 2001).  Interestingly, knock-in heterozygous p63+/- mice display 
alternative phenotypes: some have increased senescence, shortened lifespan, and 
accelerated aging phenotypes, while others develop spontaneous tumors (Flores et al., 
2005; Keyes et al., 2005). TAp63 knockout mice also display premature aging 
phenotypes, with signs of senescence, decline in wound healing, and epidermal defects 
(Su et al., 2009). Similarly, TAp73 knockout mice also have accelerated aging, primarily 
due to mitochondrial and metabolic dysfunction (Rufini et al., 2012). 
 
p53 structure and function 
Wild type p53 is able to function as a transcription factor by forming tetramers of 
four identical protein subunits. Each subunit consists of 393 amino acids that form 
highly specialized domains. p53 is composed of two N-terminal transactivation domains 
(TAD1 and TAD2), a proline rich region (PRR), a central region consisting of a 
sequence specific DNA binding domain (DBD), linker region, and tetramerization 
domain (TET), and a Carboxyl terminal domain (CTD).  
The TADs of p53 are able to interact with proteins involved in transcriptional 
machinery, including co-activators p300/CBP, PRMT1, TAFII40, and TAFII60 (An et al., 
2004; Scolnick et al., 1997; Thut et al., 1995). Recruitment of the p300 co-activator 
enables acetylation of the promoter to enhance transcription, but can also impact the 
CTD. Although mostly unstructured in solution, the TAD can interact with binding 
proteins like Replication Protein A (Leiter et al., 1996). The DBD core domain is 
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necessary for recognizing p53 response elements (p53 REs) for p53 binding and 
activation. The crystal structure of the DBD shows that the DBD coordinates with Zn2+ to 
stabilize the motif that interacts with DNA (Cho et al., 1994; Kitayner et al., 2006). The 
DBD is the site of most hotspot p53 mutations and its sequence specificity can affect 
p53 binding and lead to gain of function activities (Pavletich, 1993). The TET domain is 
critical for oligomerization of p53 and is used to form “dimer of dimers” through 
hydrophobic interactions (Lee et al., 1994).  
Although the full quaternary structure of p53 is unsolved and the amino and 
carboxyl termini of p53 appear unstructured in solution, full length p53 has been 
described by electron microscopy and nuclear magnetic resonance in two models. 
CryoEM visualization of mouse p53 stabilized with ATP suggest that each dimer is 
formed by the opposing N or C termini of two subunits  (Okorokov et al., 2006). The 
tetramer is formed through an interaction between the N/C node of one dimer and the 
core domain of another dimer. In another model, small angle x-ray scattering and 
nuclear magnetic resonance were used to analyze the shape of the p53, while electron 
microscopy provided more resolution for p53 on DNA (Tidow et al., 2007; Wells et al., 
2008). These studies suggested that the p53 tetramer exists as a cross-shaped 
structure formed primarily via TET domain interactions, with loosely coupled core DBD 
domains at the end. Further analyses suggest that the p53 tetramer slides along DNA 




p53 RE and recognition 
The p53 RE is comprised by a symmetrical 20 base pair consensus sequence of 
two half sites (5’-PuPuPuC(A/T)(T/A)GPyPyPy-3’)1 separated by a 0-13 base pair 
spacer region in target genes (el-Deiry et al., 1992; Funk et al., 1992; Zambetti et al., 
1992). Further studies continued to refine the p53 RE consensus motif, as mismatched 
and non-canonical sites allow p53 binding as well (Gohler et al., 2002). Although p53 
REs are distributed along target gene loci, they tend to cluster upstream from the 
transcription start site of most p53 target genes (Riley et al., 2008). Distance between 
the p53RE and transcription start site has been correlated with p53 transactivation 
potential. Interaction between p53 and the p53 RE is dependent on the DBD’s Zn2+ 
coordination, leading to a conformational change that displays an induced-fit for the p53 
and DNA interaction (Petty et al., 2011).  
Although the p53 binding and recognition occurs primarily through the core DBD 
that recognizes p53 RE specifically, the basic CTD of p53 can also recognize DNA 
nonspecifically (Chuikov et al., 2004; Y. Liu et al., 2006; McKinney et al., 2004). By 
allowing p53 to diffuse along naked DNA, it has been postulated that the CTD is 
involved in regulating p53 transactivation. Recently, the CTD of p53 was confirmed to 
regulate p53 binding (Laptenko et al., 2015). Mounting evidence support the idea that 
the CTD may also facilitate p53 acetylation and promoter binding (Avantaggiati et al., 
1997; Espinosa et al., 2001; W. Gu & Roeder, 1997). It is possible that the CTD could 
                                             
1 Annotations used: 
Pu: purine – adenine or guanine 
Py: pyrimidine – cytosine or thymine 
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also play an important role in basal p53 target gene expression, when p53 protein is 
maintained at low cellular levels. 
 
p53 regulation  
 p53 stabilization and modification is crucial for activating specific transcriptional 
programs to respond to stress (Brady et al., 2011). Stress conditions can vary based 
upon severity, duration, type, etc. and therefore have differential impacts on p53 protein 
dynamics that determine downstream cellular outcomes (Purvis et al., 2012). A 
multitude of stressors have been confirmed to stabilize p53 protein levels, including 
ultraviolet light, ionizing radiation, oxidative stress, DNA cross-linking agents, hypoxia, 
replicative stress, nutrient deprivation, and ribosomal stress (Bieging et al., 2014; 
Maltzman et al., 1984). Upon exposure to stress, p53 can be post-translationally 
modified through phosphorylation, acetylation, ubiquitination, SUMOlation, neddylation, 
methylation, glycosylation (Appella et al., 2001; Bode et al., 2004). In addition, 
significant cooperation between p53 post-translational modifications can lead to a 
sequential modification cascade to determine cell fate (Laptenko et al., 2006). 
 The N-terminus and C-terminal domains of p53 are heavily modified. The N-
terminus features residues that are mainly phosphorylated, which can lead to 1) p53 
stabilization through inhibition of Mdm2 interaction and 2) p53 transactivation through 
recruitment of p300/CBP (Avantaggiati et al., 1997; Shieh et al., 1997). Modifications at 
specific residues can yield discriminatory outcomes. For example, phosphorylation of 
p53 serine 15 and 20 (S15/S20; S18/S23 in mice) is necessary for full stabilization of 
p53 and subsequent cell cycle arrest or apoptosis (Chehab et al., 1999; Unger et al., 
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1999). Knock-in mice introducing alanine at these residues (S18A/S23A) confirmed that 
phosphorylation at these sites is required  for p53-dependent apoptosis (Chao, Herr, et 
al., 2006). Additionally, phosphorylation of serine 46 (S46) through Homedomain-
interacting protein kinase 2 (HIPK2) can lead to apoptosis via AIP1 (Dauth et al., 2007; 
Wesierska-Gadek et al., 2007).  
Key transducers such as ATM (ataxia telangiectasia mutated) and ATR (ataxia 
telangiectasia and Rad3-related protein) kinases also initiate signal cascades upon 
genotoxic stress in response to double strand breaks and single strand DNA, 
respectively (Kastan et al., 1992). Ionizing radiation can lead to ATM activity resulting in 
direct p53 S15 phosphorylation or Chk2 kinase activation and subsequent p53 T18/S20 
phosphorylation (Banin et al., 1998; Chehab et al., 2000; Shieh et al., 2000). UV 
radiation can drive ATR-mediated p53 phosphorylation at S15 via Chk1 kinase (Tibbetts 
et al., 1999). Altogether, they are able to stimulate p53 accumulation by disrupting the 
Mdm2-p53 interaction that requires the N-terminal domain of p53 (Shieh et al., 1997). 
The CTD of p53 on the other hand has residues that can be phosphorylated, 
acetylated, methylated, etc., which can modulate protein stability, oligomerization, 
localization of p53 (Ivanov et al., 2007). Again, cellular fate is dependent on the residue 
and modification. Several of these lysines can also be ubiquitinated to drive p53 export 
or degradation, or methylated to enhance or suppress p53 activity (M. Li et al., 2003; 
Meek et al., 2009; Rodriguez et al., 2000). Phosphorylation of serine 315 (S315) leads 
to Nanog repression, limiting stem cell renewal (Lin et al., 2005). p53 S366 and T387 
can also be phosphorylated by checkpoint kinases Chk1 and Chk2 to regulate CTD 
acetylation (Ou et al., 2005). The highly basic CTD region contains six extreme C-
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terminal lysines (K320, K372, K373, K381, K382, and K386) that can be regulated 
though acetylation to activate p53 (W. Gu & Roeder, 1997; W. Gu, Shi, et al., 1997; 
Sakaguchi et al., 1998). K320 can be acetylated by the transcription coactivator 
P300/CBP-associated factor (PCAF) under certain conditions to preferentially activate 
cell cycle arrest or axon regeneration, but reduce apoptosis (Di Giovanni et al., 2006; 
Knights et al., 2006). Knock-in mice converting this residue to arginine supported this 
finding (Chao, Wu, et al., 2006). Acetylation of lysine residues can also inhibit 
ubiquitination at these sites (M. Li et al., 2002).  
Although most post-translational modifications occur at the N and C termini of 
p53, several modifications in the DNA binding domain also exists. Acetylation of lysine 
120 (K120) or lysine 164 (K164) can preferentially lead to Puma-mediated apoptosis, 
but not Mdm2 activation. In addition, mice with 3 lysine residues replaced with arginine 
(K117, K161, K162; 3KR) mediate tumor suppression through metabolic targets, but not  
through senescence or apoptosis. (T. Li et al., 2012). Interestingly, individual lysine 
mutations can be compensative by acetylation of other lysines, as mutation of all 8 
lysine residues to arginine (8KR) also abolishes the ability of p53 to mediate cell cycle 
arrest and apoptosis, but leaves the Mdm2-p53 feedback loop intact (Tang et al., 2008). 
These data suggest that p53 lysine acetylation is crucial for differential p53 activation. 
In addition to post-translational modifications, there are many binding partners of 
p53 that are able to regulate its activity. Mdm2 is the primary negative regulator of p53 
and is essential for restraining p53 activity through mechanisms discussed later. Other 
proteins that interact with p53 include ASPP, iASPP, p18/Hamlet, and CARM1 
(Vousden et al., 2009). ASPP1 and ASPP2 can bind to p53 to induce transactivation of 
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pro-apoptotic genes, while iASPP is able to inhibit apoptosis (Bergamaschi et al., 2006; 
Samuels-Lev et al., 2001). p18/Hamlet is a p38-regulated protein that can also induce 




Murine double minute 2 (Mdm2) was initially discovered in 1991 as a potential 
causative gene in the spontaneously transformed mouse 3T3 cell line, where  several 
mdm genes were amplified by 50-fold on “double-minutes” or extrachromosomal 
nuclear bodies (Cahilly-Snyder et al., 1987; Fakharzadeh et al., 1991). Mdm2 was soon 
determined to be able to bind and inhibit p53 (Momand et al., 1992). Further studies 
demonstrated that Mdm2 was able to regulate p53 degradation and stability (Haupt et 
al., 1997; Kubbutat et al., 1997). Mdm2 was found to be overexpressed in human 
sarcomas and gliomas, confirming a role for Mdm2 in tumorigenesis (Cordon-Cardo et 
al., 1994; Leach et al., 1993; Oliner et al., 1992; Reifenberger et al., 1993).  
Mdm2 primarily functions as an E3 ubiquitin ligase. It is able to recruit ubiquitin-
loaded E2 and transfer the ubiquitin to the ubiquitin chain on its substrate. Therefore, it 
is able to both mono-ubiquitinate and poly-ubiquitinate lysine residues of its target 
proteins, including p53 and itself (S. Fang et al., 2000; Honda et al., 2000; Rodriguez et 
al., 2000). Other targets for Mdm2 ubiquitination include histone deacetylase 1 and 
insulin-like growth factor 1 receptor (Girnita et al., 2003; Kwon et al., 2016; Lipkowitz et 
al., 2011). While poly-ubiquitination typically leads to 26s proteasome degradation, 
mono-ubiquitination can lead to receptor endocytosis, DNA repair, nuclear export, 
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apoptosis, etc (Hicke, 2001). Mdm2 mono-ubiquitination is specifically involved in the 
translocation of its substrate to the nucleus and/or mitochondria (M. Li et al., 2003).  
 
Structure/domains 
Human Mdm2 is composed of 12 exons with two promoters in intron 1 (Iwakuma 
et al., 2003). Basal levels of Mdm2 are regulated via the P1 promoter, which is typically 
constitutively active at low levels in most cell types. p53-dependent Mdm2 transcription 
is driven by P2 promoter activation which has two p53 responsive elements just ahead 
of its transcription start site (Barak et al., 1994; Wu et al., 1993). Translation is initiated 
at the start codon in exon 3 and can lead to expression of full-length Mdm2 or splice 
variants (Bartel et al., 2002). Genotoxic stressors can lead to aberrant splicing of Mdm2, 
which can generate shortened versions of Mdm2 that retain its Zinc and RING fingers, 
which can still oligomerize with functional Mdm2 to inhibit its activity (Chandler et al., 
2006; Evans et al., 2001). In addition, isoforms like Mdm2-B can promote p53 gain-of-
function activities by enhancing mutant p53 accumulation (Zheng et al., 2013). 
The full-length Mdm2 protein is composed 491 amino acids and several motifs: 
an N-terminal p53-binding domain, nuclear localization signal (NLS), nuclear export 
signal (NES), unstructured acidic domain, zinc finger, RING (really interesting new 
gene) domain with a nucleolar localization signal (NoLS), and extreme C terminus 
(Figure 1.1). The p53-binding domain of Mdm2 can bind to the N-terminal 
transactivation domain of p53 (Leng et al., 1995; Oliner et al., 1993). To a lesser 
degree, the N terminal domain of Mdm2 can also interact with CTD of p53 (Poyurovsky 
et al., 2010).  
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The central acidic domain is critical for interaction with ribosomal proteins and 
p300/CBP, as well as ubiquitination of p53 (Kawai et al., 2003; Meulmeester et al., 
2003). In addition, the acidic domain is able to directly bind to the p53 DBD, as well as 
induce p53 conformational changes to inhibit p53 DNA binding ability (Cross et al., 
2011; Ma et al., 2006; Shimizu et al., 2002). The zinc finger is a key site for Mdm2 
interactions with ribosomal proteins L5 and L11 (Lindstrom et al., 2007).  
The RING finger of Mdm2 is of the C2H2C4 type and is able to chelate Zn2+ to 
promote the transfer of ubiquitin from the E2 conjugating enzyme to the lysine residue 
of p53 (Wade et al., 2010). Finally, the extreme C terminus of Mdm2 a regulatory region 
that is highly conserved across species and is essential for Mdm2 oligomerization and 
E3 ligase activity (Poyurovsky et al., 2007; Uldrijan et al., 2007). In particular, the 
aromatic resides Y487 and F490 seem to play critical roles in creating a scaffold for E2 
recruitment. A C-terminal mutational analysis demonstrated that extension of the 
extreme C-terminus of Mdm2 could impair its degradation ability, which can be rescued 
by expression of wild type Mdm2 or MdmX (Dolezelova et al., 2012).  
 
Mdm2-p53 circuit 
The Mdm2-p53 axis forms a negative regulatory loop (Figure 1.2) (Moll et al., 
2003). Mdm2 is able downregulate p53 activity via three mechanisms: 1) poly-
ubiquitination of p53 to target p53 for proteasome-mediated degradation, 2) mono-
ubiquitination of p53 leading to p53 export from the nucleus to decrease p53-mediated 
transcription and 3) direct binding to p53 to block transactivation of key targets by 
blocking a N-terminal alpha helix of p53 that is typically used to recruit transcription co-
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activators. (Wade et al., 2010). On the other side, p53 is able to promote transcription of 
Mdm2. p53 is able to bind to the RE in intron 1 of Mdm2 and activate the P2 promoter to 
upregulate Mdm2 expression (Barak, 1994).  
Under unstressed basal conditions, p53 is maintained at low levels due to 
inhibition by Mdm2. When DNA damage occurs, disruption of the Mdm2-p53 interaction 
blocks the ability of Mdm2 to ubiquitinate p53 leading to p53 stabilization which can in 
turn induce Mdm2. This loop is highly oscillatory and stressor-dependent (Batchelor et 
al., 2011; Lev Bar-Or et al., 2000). Engineered mice that are genetically null for Mdm2 
expression or express a key Mdm2 RING domain mutation that abrogates E3 ligase 
activity (C462A) display early embryonic lethal phenotypes unless present in a p53 null 
background (Itahana et al., 2007; Jones et al., 1995; Montes de Oca Luna et al., 1995). 
These mice feature developmental deficiencies and massive apoptosis, indicating that 
Mdm2 and particularly its E3 ligase function is required to restrict p53 activity. Additional 
mouse models demonstrate that that Mdm2 repression of p53 is necessary continuously 
(Ringshausen et al., 2006). 
Interestingly, the ability of Mdm2 to regulate p53 through transactivation blockage 
or degradation can be delineated. Recent structural data through X-ray crystallography 
indicate that mutations in the Mdm2 RING domain to prevent E2-ubiquitin loading can 
leave the RING structure intact, but eliminate the E3 ligase activity of Mdm2 (Nomura et 
al., 2017). Here, Mdm2 still retains its ability to regulate basal p53 through direct 




Regulation of Mdm2 P2 promoter 
 The Mdm2 P2 promoter is a nucleosome-free region that has a relative open 
chromatin state to allow transcription factor binding (Xiao et al., 1998). To stimulate 
Mdm2 expression, the promoter requires TRRAP acetyltransferase complexes, 
suggesting an active role for acetylation in Mdm2 activation (Ard et al., 2002). In 
addition to p53 binding and regulation, the Mdm2 P2 promoter is also regulated by other 
proteins in p53-independent manners. Specifically, the Ras pathway, hormone 
receptors (estrogen and thyroid hormone receptors), MYCN, and TGF- have all been 
implicated in inducing Mdm2 transcription (Araki et al., 2010; Phelps et al., 2003; Qi et 
al., 1999; Ries et al., 2000; Slack et al., 2005).  
 
Regulation of Mdm2 protein turnover 
 Mdm2 participates in an auto-regulatory feedback loop and can target itself for 
proteasome-mediated degradation (S. Fang et al., 2000; Honda et al., 2000). MdmX 
plays an important role in facilitating Mdm2 stability and will be discussed later. 
However, Mdm2 is not the only E3 ligase that can regulate Mdm2 turnover. In fact, 
PCAF has displayed intrinsic ubiquitination activity towards Mdm2 in vitro (Linares et al., 
2007). Furthermore, the Skp, Cullin, F-box containing complex SCF-TRCP can also 
ubiquitinate Mdm2 (Inuzuka et al., 2010). 
   
Oligomeric state of Mdm2 
 NMR structural data suggest that Mdm2 can form dimers mediated through the 
RING domain (Kostic et al., 2006). Functional Mdm2 can form two types of dimers: 
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homodimers with Mdm2 or heterodimers with MdmX (Leslie et al., 2016; Lipkowitz et al., 
2011). However, data from our lab indicate that Mdm2 can form supramolecular higher-
order structures in solution through the RING domain (Poyurovsky et al., 2007). 
Clarifying this discrepancy may yield more insights on how Mdm2 stoichiometry and 
structure generates intact E3 ligase activity. Meanwhile, heterodimerization between 
Mdm2 and MdmX can enhance the ubiquitination and degradation of p53 (Linares et al., 
2003; Linke et al., 2008; Okamoto et al., 2009).  
 
Post-translational modifications of Mdm2 
Many post-translational modifications can modulate Mdm2 and p53 activity 
(Meek et al., 2003). For example, DNA damage can activate ATM phosphorylation of 
Mdm2 at serine 395 (S395) to inhibit Mdm2 E3 ligase activity towards p53 (Maya et al., 
2001). Alternatively, Wip1 phosphatase can de-phosphorylate Mdm2 S395 to promote 
Mdm2 activity (Lu et al., 2007). c-Abl phosphorylation of Mdm2 at tyrosine 394 (Y394) 
has also been implicated in p53 stabilization (Goldberg et al., 2002; Sionov et al., 2001). 
In contrast, AKT phosphorylation at Mdm2 serine 186 can enhance Mdm2 ubiquitination 
and degradation of p53 (Ogawara et al., 2002). DNA-activated protein kinase DNA-PK 
can phosphorylate Mdm2 at serine 17 (S17) to hinder the interaction between Mdm2 
and p53 (Mayo et al., 1997). ATR phosphorylation of Mdm2 serine 407 can prevent 




Protein regulation of Mdm2 
 Mdm2 is able to interact with a myriad of binding partners (Fahraeus et al., 
2014). Many of these interactions relate to substrates and cofactors for its E3 ligase 
activity, but Mdm2 can also be directly regulated by protein binding. For the purposes of 
clarity, we will focus on proteins that can complex with Mdm2 to promote p53 
degradation and potentially augment tumorigenesis. For example, -arrestin-2 can 
promote cytoplasmic localization of Mdm2, thereby inhibiting the ability of Mdm2 to 
target p53 (Boularan et al., 2007; Wang et al., 2003). -arrestin-1 can also facilitate 
Mdm2 activation via ATM (Hara et al., 2011). Enigma and COP9 signalosome are also 
able to diminish the ability of Mdm2 to regulate p53 with tumorigenic effects in mice 
(Jung et al., 2010; Zhao et al., 2011). The transcription factor Yin Yang 1 is also able to 
perturb Mdm2-p53 interactions to negatively regulate p53 (Sui et al., 2004). In addition, 
Mdm2 can interact with p53 family members p73 and p63 to varying extents (Calabro et 
al., 2002; Dobbelstein et al., 1999; Kadakia et al., 2001; Stindt et al., 2015). Another 
method for Mdm2 to enhance p53 degradation is through its association with the 26s 
proteasome (Kulikov et al., 2010). This function of Mdm2 is regulated by 
phosphorylation of its acidic domain and is mediated through binding by both the N-
terminal and C-terminal domains with the 19s cap. HAUSP can de-ubiquitinate and 
stabilize Mdm2 in a p53-independent manner (M. Li et al., 2004).  
 Ribosomal proteins (RP) are another source of Mdm2 interaction partners 
(Zhang et al., 2009). RPs such as RPL11, RPL5, RPS7, RPS3, and RPL26 are 
released from the nucleolus upon induction by ribosomal stress (Dai et al., 2004; Takagi 
et al., 2005; Yadavilli et al., 2009; Zhu et al., 2009). These ribosomal proteins generally 
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bind to the central region of Mdm2, but play multiple roles in activating p53. Some 
ribosomal proteins like RPL11 and RPL5 will act through Mdm2 to inhibit p53 
ubiquitination and degradation, while others like RP26 will increase p53 mRNA 
translation. RPL37, RPS15, and RPS20 can regulate p53 target gene expression 
(Daftuar et al., 2013).  
 Oncogenic stresses can activate p19ARF to regulate Mdm2-p53 activity (Palmero 
et al., 1998; Zindy et al., 1998).  Specifically, p19ARF leads to Mdm2 inhibition and p53 
stabilization (Pomerantz et al., 1998; Zhang et al., 1998). Several models have been 
proposed on the mechanism behind inhibition of Mdm2. Three models focus on 
nucleolar localization: p19ARF can bind to and sequester Mdm2 in the nucleolus, induce 
a conformational change to reveal the Mdm2 cryptic NoLS, or prevent Mdm2 nucleolar 
exit (Lohrum et al., 2000; Tao et al., 1999; Weber et al., 1999). A third model suggest 
that p19ARF, p53, and Mdm2 form nuclear bodies that activate p53 through inhibition of 
p53 nuclear export (Zhang et al., 1999).  
   
p53-independent activities of Mdm2 
 Mdm2 also has a number of p53-independent functions that can promote 
tumorigenesis (Ganguli et al., 2003; Q. Li et al., 2013). Overexpression of Mdm2 
predisposed mice for sarcoma development both in the presence or absence of p53 
(Jones et al., 1998). At a functional level, Mdm2 can inhibit tumor suppression functions 
of cell cycle arrest, apoptosis, and genome damage repair and enhance proliferation. 
For Mdm2 can directly bind to and stimulate E2F1 and NF-B activity to drive 
proliferation (Martin et al., 1995; Thomasova et al., 2012). Mdm2 also plays a role in 
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estrogen-mediated breast cancer proliferation (Brekman et al., 2011). In order to 
promote genome instability, Mdm2 can bind to and inhibit NBS1, a protein involved in 
double-strand break repair (Alt et al., 2005). Additionally, Mdm2 can inhibit apoptosis by 
either enhancing anti-apoptotic XIAP translation through binding to its 5’ UTR or 
facilitating the degradation of the transcription factor FOXO3a (L. Gu et al., 2009; J. Y. 




Human MdmX (mouse Mdm4) is composed of 490 amino acids and is a 
structural homolog of Mdm2. Although MdmX has p53 binding and RING domains, 
MdmX does not retain any E3 ubiquitin ligase activity (Shvarts et al., 1996; Stad et al., 
2000). However, the RING domain of MdmX does share a similar binding affinity as 
Mdm2 to adenine nucleotides, suggesting that some of the domain’s function is 
conserved (Priest et al., 2010). Despite being unable to ubiquitinate substrates, MdmX 
is nevertheless still able to negatively regulate p53 and has oncogenic properties 
(Danovi et al., 2004).  Therefore, MdmX is often overexpressed in tumors with wild-type 
p53, such as gliomas, head and neck squamous carcinomas, etc. (Ramos et al., 2001; 
Riemenschneider et al., 1999). MdmX can also stabilize Mdm2 protein by inhibiting its 
auto-ubiquitination (Sharp et al., 1999; Stad et al., 2000).  
As discussed earlier, MdmX can form heterodimer complexes with Mdm2 to 
promote p53 ubiquitination and degradation (Linares et al., 2003; Linke et al., 2008; 
Okamoto et al., 2009). In mice, this heterodimerization is crucial for regulating p53 
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activity during embryogenesis (Pant et al., 2011). Furthermore, the extreme C terminus 
of MdmX can recapitulate functions of Mdm2 to directly enable Mdm2 E3 ligase activity 
(Uldrijan et al., 2007).  
 
Role of MdmX in p53 regulation 
Similar to Mdm2 knockout mice, MdmX null mice are embryonic lethal (Migliorini 
et al., 2002; Parant et al., 2001). However, this lethality occurs a few days later in 
development and is a consequence of cell cycle arrest instead of apoptosis. These 
studies suggest that Mdm2 and MdmX regulate p53 target gene specificity, leading to 
distinct cellular outcomes. Additionally, MdmX can contribute to alternative gene 
expressions through regulation of chromatin remodeling cofactors, transcription factors, 
and post-translational modifiers (Biderman et al., 2012). 
 
Aging and the Mdm2-p53 axis 
Aging 
Aging is the gradual process of cellular deterioration due to cumulative molecular 
changes over time. At the organismal level, the aging phenomenon is often 
characterized by outward phenotypes such as shortened stature, decreased lifespan, 
skin abnormalities, and graying of the hair. The underlying molecular mechanisms of 
aging feature the depletion of healthy, functional cells leading to tissue and organismal 
degeneration (Campisi, 2013). This cellular turnover is often attributed to both stem cell 
exhaustion and the gradual senescence of cells, most notably through telomere 
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shortening (replicative senescence) and through cumulative genomic damage (Balaban 
et al., 2005; Vousden et al., 2009).  Cells undergo senescence when they are unable to 
continue dividing. Instead, these cells adopt more flattened morphologies, declined 
stress response signaling, and a general loss of homeostatic balance (Linskens et al., 
1995; Serrano et al., 1997). Over time, the number of senescent cells in an organism 
can accumulate and develop the senescence-associated secretory phenotype (SASP), 
producing a chronic inflammatory microenvironment that can accelerate the aging 
process (Coppe et al., 2008; Rodier et al., 2009).  
 
Human Aging Disorders 
The study of age-related diseases and accelerated aging disorders (progeroid 
syndromes) are not only valuable in furthering our understanding of specific 
pathologies, but also for understanding the broader aging phenomenon. In contrast to 
cancer where cells gain fitness to proliferate rapidly and uncontrollably, aging features 
cells that lose fitness (Campisi, 2013; Lopez-Otin et al., 2013). How cells respond to 
DNA damage is usually the determining factor between these two choices. p53 is a 
master regulator that has been linked to human diseases from development through old 
age. Proper p53 regulation is required for development, as evidenced by Mdm2 
knockout mice that are embryonic lethal unless generated in a p53-null background 
(Jones et al., 1995; Montes de Oca Luna et al., 1995). Wild type p53 function is required 
for tumor suppression, as germline p53 mutations in Li-Fraumeni patients lead to 
increased cancer incidence (Malkin et al., 1990). p53 has also been implicated in 
neurodegenerative disorders: p53 is upregulated in Alzheimer’s disease and is able to 
22 
 
interact with huntingtin and mediate neuron cell death in Huntington’s disease (Hooper 
et al., 2007; Steffan et al., 2000). However, the question of whether p53 aids or negates 
the aging process remains complex, as p53 activity has been associated with both 
premature aging and longevity. 
Progerias are often characterized by early onset and rapid progression, with 
patients displaying accelerated phenotypes and shorter lifespans (Navarro et al., 2006). 
Although progerias only partially phenocopy normal aging, their study provides insights 
into the mechanisms underlying aging. In many cases, progeria is monogenic and 
driven by defects in DNA repair mechanisms. For example, aberrant nucleotide excision 
repair (NER) has been associated with cerebro-oculo-facio-skeletal syndrome (COFS), 
trichothiodystrophy (TDD), and Cockayne syndrome (CS) (Marteijn et al., 2014). 
Additionally, deficiencies in non-homologous end-joining (NHEJ) have been associated 
with Werner’s Syndrome and ataxia telangiectasia (Hasty et al., 2003). Still other 
progerias such as laminopathies feature disruption of the nuclear architecture via lamin 
processing, leading to chronic stress and activation of the p53 pathway (B. Liu et al., 
2005; Navarro et al., 2006; Varela et al., 2005). Collectively, these progerias also share 
a common feature of genomic instability, a characteristic which could either be 
considered a downstream effector or an upstream driver of aging-mediated stress 
signaling. 
Alternatively, several studies have implicated diminished p53 activity with 
longevity, which is consistent with increased cancer incidences in aging populations 
(Feng et al., 2007). Naturally aged mice experience a decline in p53 function at the 
transcriptional and protein levels, suggesting that their tumor suppressive functions may 
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be compromised (Feng et al., 2007). Another example is the p53 polymorphism 
Arg72Pro, which has been associated with increased longevity in humans (Orsted et al., 
2007). However, although Arg72Pro appears to reduce the p53 apoptotic response, no 
significant change in cancer incidence was observed (Dumont et al., 2003; Orsted et al., 
2007). Additionally, model systems such as C. elegans and Drosophila associate loss of 
p53 with extended lifespan, suggesting that p53 activity could play a major role in 
regulating metabolic pathways such as insulin-like growth factor/mTOR.  
 
p53 and the hallmarks of aging 
Lopez-Otin et al enumerate nine key hallmarks of aging in their landmark review 
(Lopez-Otin et al., 2013). The p53 pathway is a master regulator of many of these 
hallmarks, including genomic instability, dysfunction, and cellular senescence. 
 
Genome instability 
As mentioned earlier, genomic instability is prevalent as genomic damage 
accumulates over time. One of the main functions of p53 is to maintain genomic 
integrity through repair and cell cycle arrest mechanisms to limit proliferation of 
damaged cells. This potentially explains why many progerias with defective repair DNA 
mechanisms often exhibit genomic instability and subsequent elevated p53 activity 
(Vousden et al., 2009). However, dependent on the level and type of stress (acute or 
chronic), activation of certain p53 target genes will lead to manifestation of differential 





As organisms age, mitochondrial dysfunction occurs and respiration efficiency 
decreases (Kujoth et al., 2005). As the energy generators of the cell, mitochondria 
require regular maintenance through mitochondrialDNA (mtDNA) repair and mitophagy, 
an organelle-specific clearance of damaged mitochondria. Part of the mitochondrial 
deterioration can be attributed to increased production of reactive oxygen species 
(ROS). However, simple elevation of ROS is insufficient to accelerate aging, and has in 
fact prolonged lifespan in yeast and C. elegans (Doonan et al., 2008). In contrast, 
defects in proofreading mtDNA enzymes have led to accelerated aging phenotypes in 
mice (Trifunovic et al., 2004). Therefore, it is likely that collective mitochondrial 
dysfunction due to increased damage and reduced turnover could affect cell signaling, 
autophagy, and aging. 
The p53 transcriptional program and metabolism and mitochondrial health is 
sometimes paradoxical. While p53 is able to promote ROS production when its 
mediating apoptosis, p53 is also able to induce expression of anti-oxidant genes. 
Normal basal activity of p53 has been implicated in optimizing mitochondrial respiration 
and reducing ROS through SCO2 (Matoba et al., 2006), GLS2 (Hu et al., 2010; Suzuki 
et al., 2010), TIGAR (Bensaad et al., 2006), and sestrins (Budanov et al., 2004), and 
more (Budanov, 2014). In addition, p53 mediates nucleus-mitochondria signaling to 
further regulate mitochondrial integrity (E. F. Fang et al., 2016). However, upon acute 
stress p53 can activate pro-oxidant targets to mediate apoptosis (Figure 1.3). The 
mTOR pathway further complicates the p53-metabolism link is. Activation of mTOR can 
lead to reduced expression of the histone deacetylase SIRT1, which can in turn 
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modulate p53 activity. SIRT1 is also involved mitochondrial biogenesis with the 
transcriptional co-activators PGC-1. In response to telomere attrition, p53 is able to 
mediate repression of PGC-1a and PGC1-b, thereby increasing ROS, mTOR activity, 
and mitochondrial dysfunction in a feedback loop (Sahin et al., 2012). 
 
Cellular Senescence 
Perhaps the most commonly associated phenotype of aging, senescence 
represents a stable, irreversible arrest in the cell cycle (Kuilman et al., 2010; Rufini et 
al., 2013). Although primarily triggered by telomere attrition, exposure to physiological 
stresses can also lead senescence. Two key pathways have been linked to 
senescence: p16INK4a/RB and p53/p21. p16INK4a is able to block cell cycle progression 
by inhibiting cyclin D – CDK4/6 complexes, thereby activating Rb to inhibit E2F 
transcriptional effects. p53 is able to activate p21 and PAI-1 to mediate cell cycle arrest 
and senescence. The buildup of senescent cells, combined with minimal healthy cell 
turnover and slowed division of healthy cells, is largely thought to drive aging 
phenotype, while clearance of senescent cells has been associated with a delay of 
aging effects (D. J. Baker et al., 2011).  
Accumulation of senescent cells often lead to chromatin reorganization and the 
SASP, which includes secretion of pro-inflammatory chemokines, cytokines, growth 
factors, matrix metalloproteases, etc (Campisi, 2013). SASP can therefore lead to 
paracrine signaling to induce further cellular senescence, extracellular matrix 
deterioration, and disruption of the local microenvironment (van Deursen, 2014). 
Although the inflammation can attract an immune response, certain SASP conditions 
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harbor immune-evasion proteases that can avoid clearance of senescent cells, thereby 
propagating further senescence and aging phenotypes. 
 
Aging Mouse Models 
Premature aging models 
Mouse models are useful in understanding human physiological systems, 
particularly since genome maintenance genes are conserved across species. Several 
mouse models have been developed to model progerias, including Hutchinson-Gilford 
Progeria Syndrome (HGPS) and Trichothiodystrophy (TTD) (Table 1.1). HGPS is driven 
primarily by lamin processing defects. Zmpste24-/- mice exhibit HGPS symptoms, 
upregulated p53 target genes, and premature senescence, though basal levels of p53 
remain unchanged (Varela et al., 2005). The Zmpste24-/- aging phenotype is partially 
rescued upon crossing in a p53 null background. Similarly, Ku86-/- mice also present 
with gray hair, dermal atrophy, and early senescence, but is driven through defective 
double-strand break repair instead of chronic nuclear stress (Vogel et al., 1999). Unlike 
other accelerated aging models that are rescued upon p53 knockout, ATR-Seckel mice 
display an exacerbated phenotype when p53 is lost (Murga et al., 2009). This could 
possibly be due to p53 loss overwhelming the mouse with additional genomic instability, 
when ATRS/S mice already exhibit high levels of embryonic replicative stress and 
shortened lifespans. Similarly, adult p53-/-ATRmKO mice generated with flox-regulated 
mosaic ATR deletion display increased damage, tissue degeneration, and die within 2 
weeks, further confirming  the importance of the ATR-p53 pathway in regeneration 
(Ruzankina et al., 2009). 
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Mouse models focusing on the role of telomere shortening have also directly 
connected senescence to aging. When the RNA component of telomerase is knocked 
out, the resulting mTR-/- mice have decreased lifespan, shortened telomere lengths 
across six generations, increased senescence, and infertility at G6 (Blasco et al., 1997; 
Rudolph et al., 1999). In addition, they have greater skin lesions, delayed wound 
healing, and increased genomic instability. Moreover, late generation mTR-/- mice have 
greater induction of p53 and p21 and experience more apoptosis in certain tissues. This 
phenotype can be rescued by p53 loss, despite the telomere dysfunction (Chin et al., 
1999). Similarly, elimination of p53 or p16INK4A to reduce senescence can rescue the 
aging phenotype in mice with defects in BRCA1 and BubR1 (D. J. Baker et al., 2011; 
Cao et al., 2003; Varela et al., 2005). On the opposite end of the spectrum, constitutive 
expression of telomerase reverse transcriptase (TERT) in mice with overexpressed 
p53/p16INK4A6/p19ARF improves fitness and delays aging (Tomas-Loba et al., 2008). 
 
Mdm2/p53 mouse models 
There have been conflicting reports linking p53 elevation and aging in mice 
(Table 1.2). Although several lines of evidence support this relationship, it is obvious 
that the aging phenotype is more complex than first indicated. Two hypothetical factors 
seem to stand out in driving p53 aging phenotypes: aberrant p53 regulation or shifting 
differential p53 outcomes (Figure 1.4).  
In particular, two studies involving mice with one functional copy of wild type p53 
and one copy of an N-terminal truncation of p53 display accelerated aging phenotypes 
(Maier et al., 2004; Tyner et al., 2002). The site of the p53 alteration is important, as the 
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N-terminus of p53 is the primary interaction site with Mdm2, suggesting that Mdm2 is 
unable to properly regulate p53 in these mice. The first study emerged in 2002 from the 
Donehower group, who found that mice with a heterozygous p53 mutation (p53+/m) had 
hyperactive p53 (Tyner et al., 2002). Although basal p53 protein levels were similar in 
p53+/m and p53+/+ kidney cells, the p53 response in these mice were augmented. The 
p53+/m mice were also highly resistant to cancer, with a sporadic tumor formation of 6% 
compared to 45% for p53+/+ mice. Most notably, the p53wt/m mice displayed an 
unexpected phenotype of accelerated aging, with skeletal defects and organ atrophy. A 
follow up study indicated that the m allele produced a protein that was able to interact 
with, stabilize, and facilitate the nuclear localization of wild type p53 under basal 
conditions (Moore et al., 2007). A similar mouse model by the Scrable group in 2004 
found that overexpression of a naturally occurring p53 isoform, p44, in the presence of 
full length p53 also led to accelerated aging phenotypes (Maier et al., 2004). p44 is a 
protein that lacks the transactivation domain of p53, as translation is initiated from 
codon 41 of exon 4 in p53. Interestingly, MEFs from both p44 and p53m/-mice express 
normal p53 protein levels but have constitutively active p53 likely stemming from 
aberrant regulation of p53 by Mdm2 due to the N-terminal truncation.  
Phosphorylation of the N-terminus of p53 to disrupt the Mdm2-p53 interaction 
can also lead to aberrant p53 regulation. p53 T21D and S23D knock-in mice generated 
by the Xu group exhibited accelerated aging phenotypes (D. Liu et al., 2010). 
Constitutive p53 activation, hematopoietic degeneration, testicular atrophy, and adult 
stem cell depletion were observed in these mice. Elimination of Puma was able to 
rescue the segmental progeria phenotype in p53TSD/- mice, indicating that the aging 
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phenotype in these mice was primarily mediated through apoptosis of the adult stem 
cell pool. 
Regulation of p53 via Mdm2 adds an additional layer of complexity to 
understanding the p53 pathway connection to aging (Figure 1.5). Engineered mice that 
are genetically null for Mdm2 expression or expressing a key Mdm2 RING domain 
mutation that abrogates E3 ligase activity (C462A) display an early embryonic lethal 
phenotype unless present in a p53 null background (Itahana et al., 2007; Jones et al., 
1995; Montes de Oca Luna et al., 1995). These mice indicating that complete liberation 
of p53 from the repressive hold of Mdm2 leads to massive apoptosis and developmental 
deficiencies.  However, in a conditional mouse model, the Jones group found that 
deletion of Mdm2 in the epidermis induces p53-mediated senescence and accelerated 
aging phenotypes in the skin, including decreased wound healing ability and skin 
thinning (Gannon et al., 2011).  Notably, p53 activation in the epidermis did not lead to 
upregulation of pro-apoptotic genes, just senescent targets. It is possible that this 
observation is tissue-specific. 
Mounting evidence suggest that regulation of p53 is a critical component of 
aging, as simple elevation of p53 levels is insufficient in driving the accelerated aging 
phenotype. The Serrano group found that mice expressing super-p53 via introduction 
multiple transgenes of wild type p53 are highly cancer-resistant, but do not display signs 
of early aging (Garcia-Cao et al., 2002). Furthermore, super ARF/super p53 mice 
experience delayed-onset aging instead (Matheu et al., 2007). The Perry group sought 
to increase p53 levels through Cre-mediated Mdm2 ablation instead by generating 
Mdm2puro/Δ7-12 mice(Mendrysa et al., 2006). Despite the 70% ablation of wild-type 
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Mdm2, basal p53 protein levels were normal. p53 activity in Mdm2puro/Δ7-12 mice was 
heightened nevertheless and tumor resistance increased. Although these mice were 
about 15% smaller in size, radiosensitive, and displayed hematopoietic deficiencies, the 
mice did not age prematurely. Combined, these studies indicate that although super-
active p53 can be associated with accelerated aging, total p53 levels may not be 
directly responsible. Instead, specific functions of p53 may be a contributing factor.  
Indeed, a study by the Lozano group confirmed that downstream-targets of p53 
manifest different phenotypes. They engineered mice that lack the Mdm2 p2 promoter, 
thereby abolishing Mdm2 as a p53 transcriptional target. Although Mdm2P2/P2 mice age 
normally, homozygous Mdm2PND/PND mice serendipitously generated from a mutant P2 
promoter, neomycin cassette, and partial intron 3 deletion had shorter lifespans, skin 
hyperpigmentation, and hematopoietic defects (Pant et al., 2016; Pant et al., 2013). 
Interestingly, Puma deficiency rescued some of the reproductive defects, but p21 loss 
did not rescue any aging-related abnormalities, indicating that the apoptotic pathway 
was likely responsible for this particular phenotype. 
In contrast, the Sluss group generated knock-in mice with p53S18A, removing an 
ATM phosphorylation site that is necessary for Puma-mediated apoptosis. As expected, 
this mutation led to a high cancer incidence. Surprisingly, the non-tumor bearing mice 
presented with accelerated aging signs (Armata et al., 2007). Cells from these p53S18A 
mice had a diminished apoptotic response and underwent premature senescence.  
XRCC4 knockout mice are embryonic lethal, unless rescued via co-committal 
knockout of p53(Gao et al., 2000). XRCC4 is a protein involved in stabilization of a key 
ligase in the non-homologous end joining pathway that repairs double-strand breaks. 
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Similar to the p53S18A mice, p53S18A/S23A mice generated by the Xu group are also 
apoptosis-resistant, and thusly highly tumorigenic (Chao, Herr, et al., 2006). 
Interestingly, the p53S18A/S23A background can rescue the lethality of XRCC4-/- and 
display accelerated aging phenotypes (Chao, Herr, et al., 2006). This suggests that 
p53’s apoptotic functions are not required for genomic instability-driven aging 
phenotypes. This idea is supported by recent evidence from the Gu group, who 
demonstrated that XRCC4-/- lethality can also be rescued in a p533KR/3KR background (T. 
Li et al., 2016). p53 3KR is an acetylation-defective mutant that is unable to induce cell-
cycle arrest, senescence, and apoptosis. The authors speculate that the high levels of 
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Figure 1.1 Mdm2 Structure 






Figure 1.2 Mdm2-p53 regulatory feedback loop 
Schematic of the main mechanisms through which Mdm2 regulates p53 and itself. 






Figure 1.3 p53 pathway 






Figure 1.4 p53 regulation and aging phenotypes 
Hypothesis of how p53 regulation is linked to aging in mouse models 
 





Figure 1.5 Mdm2 and p53 need to be balanced for normal development 
Proper regulation (balance) of p53 is needed for normal aging. Aberrant regulation can 
lead to tumorigenic, accelerated aging, or lethal phenotypes. 
 





Table 1.1. Premature aging mouse model 
List of accelerated aging mouse models associated with defects in lamin processing, 









Table 1.2. Mdm2/p53 mouse models  
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The tumor suppressor p53, a master regulator of the cellular response to stress, 
is tightly regulated by the ubiquitin ligase Mdm2 via an auto-regulatory feedback loop. In 
addition to its well established role in tumorigenesis, p53 has also been associated with 
aging in mice. Several p53 mouse models with aberrant increased p53 activity display 
signs of premature aging. However, the relationship between dysfunction of the Mdm2-
p53 axis and human aging remains elusive. Here, we identified an anti-terminating 
homozygous germline mutation in MDM2 in a patient affected by a segmental progeroid 
syndrome. We show that this mutation abrogates Mdm2 E3 ligase activity, thereby 
resulting in enhanced levels and stability of p53. Analysis of patient’s primary cells, 
followed by genome-edited cells, and in-vitro and in-vivo analyses confirm the aberrant 
regulation of p53 activity by this mutation. Functional data from a zebrafish model 
further demonstrate that mutant Mdm2 is unable to rescue a p53-induced apoptotic 
phenotype. Altogether, our findings indicate that the mutant MDM2 is a likely driver of 






p53 is a DNA sequence-dependent transcriptional regulator of a myriad of genes 
whose products mediate diverse physiological pathways involved in cell cycle 
progression, apoptosis, senescence, autophagy, genomic stability, fertility, stem cell 
differentiation, and cellular metabolism (Krizhanovsky et al., 2009; Vousden et al., 
2009). Heterozygous germline mutations in the p53 encoding gene TP53 cause Li-
Fraumeni syndrome, an autosomal dominant and highly penetrant early-onset cancer 
predisposition syndrome (Malkin et al., 1990). In addition, inactivating somatic TP53 
mutations have been identified in the majority of human tumors, establishing p53 as a 
key tumor suppressor gene (Vogelstein et al., 2000). Under basal conditions, p53 is 
maintained at very low cellular levels. However, in response to exogenous and 
endogenous stressors, p53 is rapidly stabilized and activated, leading to one or more of 
the abovementioned cellular outcomes. Maintenance of low p53 levels or deactivation of 
p53 during recovery from stress is mostly attributable to the function of the E3 ubiquitin 
ligase Mdm2, which controls cellular p53 levels and activity through at least three 
mechanisms: (i) direct binding and blockage of p53 transactivation ability, (ii) mono-
ubiquitination leading to export of p53 out of the nucleus, and (iii) poly-ubiquitination 
leading to proteasomal degradation of p53 (Lee et al., 2010). In fact, Mdm2 is itself a 
direct transcriptional target of p53, thereby forming an auto-regulatory feedback loop 
such that p53 and Mdm2 tightly regulate each other's cellular levels and activities 




Whereas it is well established that p53 loss of function increases the risk for 
cancer, the relationship between dysfunction of the Mdm2-p53 axis and human aging 
remains elusive. This is an interesting question especially in light of the envisaged 
therapeutic use of Mdm2 inhibitors in oncology (B. Zhang et al., 2015). The putative 
relevance of p53 action in aging is also reflected by mouse models. Mice with N-
terminal truncations of p53 in the presence of functional wild type p53 display 
accelerated aging phenotypes (Maier et al., 2004; Tyner et al., 2002), whereas super-
p53 and hypomorphic MDM2 mice display no signs of premature aging (Donehower et 
al., 2009). Additionally, mice with N-terminal p53 mutations that mimic phosphorylation 
have constitutively active p53 activity and display segmental progeria (Liu et al., 2010). 
These results suggest that simple elevation of p53 levels is insufficient to cause 
premature aging, as p53 is still tightly regulated in the latter cases. However, complete 
liberation of p53 from the repressive hold of Mdm2 in engineered Mdm2-knockout mice 
leads to massive apoptosis and an embryonic lethal phenotype that can only be 
rescued in a p53-null background (Lozano, 2010). On the contrary, a mutation in the C-
terminus (p.Tyr487Ala) of Mdm2 is not lethal, and these mice apparently age normally 
(Tollini et al., 2014).  
Here we present a patient affected by a segmental progeroid syndrome in whom 
we identified a homozygous germline MDM2 mutation resulting in dysfunction of the 





Materials and methods 
 
Patient and samples.  
All biological samples and images were obtained following written informed 
consent from affected individual. 
 
Cell lines.  
Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) and 
primary dermal fibroblasts were established as previously described (Huang et al., 
2006). LCLs of previously used unaffected individual AG1010 (Lessel et al., 2015), 
termed “control LCL”, were used in all experiments. In experiments with primary dermal 
fibroblasts a previously used cell line of a healthy individual 82-6 (Lessel et al., 2014), 
termed “control fibroblasts 1“ was used for all experiments. To corroborate the findings 
in some experiments, additional cell lines of unaffected individuals (IMR-90, NHDF, 
1101-SK) were used, termed “control fibroblasts 2, 3 and 4,” respectively. 88-1 normal 
fibroblasts were also used. Primary dermal fibroblasts were maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum. LCLs were 
maintained in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% 
fetal bovine serum. For replicative capacity studies, primary dermal fibroblasts of the 
index patient and control fibroblasts 1 were thawed at passage 6 and passaged at 80% 
confluency. Fibroblasts were not allowed to become fully confluent at any time in order 
to maintain maximal growth rates. Human osteosarcoma (U2OS) and non-small cell 
74 
 
lung cancer (H1299) cell lines were also maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum. 
 
Homozygosity mapping and candidate gene sequencing.  
Genome-Wide Human SNP Array 6.0. (Affymetrix, Inc., Santa Clara, CA, USA) 
was used to exclude the possibility of genomic rearrangements and map putative 
homozygous regions. Genome-wide homozygosity scores were produced by 
HomozygosityMapper, a web-based approach to homozygosity mapping.(Seelow et al., 
2009) Data handling, evaluation, and statistical analysis have been described in detail 
before.(Lessel et al., 2014) For candidate gene analysis, we designed intronic primers 
to PCR amplify coding exons and the respective exon-intron boundaries by using 
genomic DNA of the affected individual. All primer pairs are available upon request. 
PCR products were sequenced on an ABI 3730 DNA Analyzer with BigDye chemistry 
v3.1 (Applied Biosystems). Sequence traces were assembled, aligned, and analyzed 
with Seqman software (DNASTAR Lasergene). 
 
Exome sequencing analysis.  
Exome sequencing of the proband was performed on two lanes of an Illumina 
GAIIx Sequencer using a single read 150 bp protocol after enrichment of exonic and 
splice-site sequences with the Agilent SureSelect Human All Exon 50 Mb kit. More than 
194 million reads were mapped to the hg19 human reference genome. Approximately 
93% of target sequences were covered at least 10-fold and 75 % 30-fold with a mean 
coverage of about 91x. Data analysis of filter-passed reads was performed with the in-
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house pipeline V1.3 using BWA-short in combination with SAMTOOLS pileup 0.1.7 for 
the detection of single nucleotide polymorphisms (SNPs) and short insertions and 
deletions (indels). In-house developed scripts were applied to detect protein changes, 
affected splice sites and overlaps to known variations, with filtering against dbSNP build 
138, the 1000 Genomes Project data build November 2014, ExAC Browser (status from 
April 2015) and the in-house database of exome variants (with data from >200 exomes 
of individuals affected by different disorders). The criteria for a variation to be taken into 
account were: >6 reads, phred scaled quality score >15, population allele frequency 




 Full-length zebrafish mdm2 and p53, and human MDM2 cDNA´s were cloned 
into pCS2+ and pcDNA3.1 (Invitrogen), respectively. Mutants were cloned using PCR 
amplification and restriction enzyme digestion and recombination. Site-directed 
mutagenesis was performed by PCR to introduce desired mutations. The correctness of 
the DNA sequence was verified by sequencing. 
 
Genome edited cell lines.  
Two TALEN plasmids were designed to target nucleotides within the intron 
between exons 10 and 11 (taccttagacatagcaaa[G]ttgctagcattcctgtgactgagcagtta where 
[G] indicates a TALEN cutting site and the two TALEN binding sites are underlined 
bold), as recommended by ZiFiT Targeter software 
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(http://zifit.partners.org/ZiFiT/TALZiFiTNuclease.aspx). A donor vector with two 1 kb 
homologous arms plus an FNF selection cassette (Frt-EM7- NeoR-Frt) was also 
constructed. The FNF selection cassette was inserted into the intron between exons 10 
and 11 of the mdm2 gene to facilitate clone selection as well as a unique HindIII site in 
exon 11. A T to C mutation was introduced into the donor vector at the stop codon TGA 
by site-directed mutagenesis. This results in an MDM2 variant with 5 amino acids 
extension. The donor and TALEN plasmids were transfected into U2OS cells followed 
by selection with G418 (800 μg/ml) for 2-3 weeks. The resistant clones were expanded 
and examined for FNF insertion on the mdm2 locus by PCR. The corrected clones were 
confirmed by sequencing to ensure that the allele carrying the mutation is corrected. 
Both heterozygous and homozygous clones were obtained. To serve as controls, 
isogenic wild-type clones were also obtained through the same selection process. 
Mutant Mdm2 p53 knockout cells were generated using CRISPR/Cas9 genome 
editing technology. Cells (7x105) were transfected with 2 μg p53 CRISPR/Cas9 KO 
plasmid (Santa Cruz Biotech). Two days later, cells were treated with Nutlin-3 (10 μM) 
for 6 days to inhibit proliferation of cells with wild type p53, thereby enriching for p53 
knockout cells. Single cell clones were selected via limiting dilution, and p53 knockout 
clones were confirmed by Western blotting using FL-393 (Santa Cruz Biotechnology) 
rabbit polyclonal antibody. 
 
Immunoblotting.  
Whole cell lysates were analyzed by standard immunoblotting procedure. Protein 
concentration was measured using the Bio-Rad protein assay (Life Science Research, 
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Hercules, CA). Equal amounts of total protein were resolved on 8% or 12% 
polyacrylamide gels (for ectopic or fibroblast/LCL work respectively), transferred to a 
nitrocellulose membrane, then blocked for 30 min in phosphate-buffered saline 
containing 0.1% Tween 20 (PBST) (Sigma-Aldrich, St. Louis, MO) and 5% nonfat dry 
milk. The membrane was incubated overnight at 4°C with primary antibodies in 1% milk 
PBST. Commercial primary antibodies used include anti-FLAG (M2, Sigma), anti-HA 
(6B12, Covance), p53 (AF1355, R&D systems), Mdm2 (N20 or H-221, Santa Cruz 
Biotechnology), phospho(Ser15)-p53 (Cell Signaling), Lamin B1 (S20, Santa Cruz 
Biotechnology), p21 (C-19, Santa Cruz Biotechnology), anti-GFP (B2, Santa Cruz 
Biotechnology), γ-tubulin (T5192-Sigma) and anti-actin (A2066, Sigma). Monoclonal 
antibodies used as in-house produced hybridoma supernatants include p53 (1801/DO-
1) and Mdm2 (2A9, 3G5, 4B11, and 5B10). After three washes with PBST, membranes 
were incubated with secondary antibodies in 1% milk PBST for 30 min at room 
temperature. Secondary antibodies used included goat anti-mouse or goat anti-rabbit 
conjugated to horseradish peroxidase (Sigma) or fluorescent green goat-anti mouse, 
and fluorescent red donkey anti-rabbit (IRDye 800CW and IRDye 680LT, LI-COR 
Biosciences). Membranes were visualized either with ECL (GE Healthcare or Thermo 
Scientific) or the Odyssey Imaging System (LI-COR Biosciences). 
 
Drugs.  
Drugs used were Nutlin-3 (a racemic mixture of the active Nutlin-3a and inactive 
Nutlin-3b, Sigma), cycloheximide (Calbiochem), daunorubicin (Sigma), MG132 
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(Calbiochem), mitomycin C (Sigma), cytochalasin B (Sigma), aphidicolin (Sigma) and 
adriamycin (Sigma).  
 
Immunofluorescence analyses.  
U2OS, control 1 and IV:7 primary fibroblasts were grown on coverslips in 35 mm 
petri dishes. Cells were washed twice with PBS and fixed with 4% paraformaldehyde 
solution in PBS for 20 min at room temperature (RT). Following two additional washes, 
fixed cells were permeabilized with 0.5% Triton X-100 in PBS at RT for 1.5 min, washed 
twice, blocked with 0.5% bovine serum albumin in PBS for 30 min at RT, incubated with 
primary antibodies at RT for 1 h in blocking solution, washed thrice, incubated with a 
mixture of secondary antibodies conjugated with fluorescent dye (Alexa Fluor 488 and 
Alexa Fluor 594, Life Technologies) at RT for 1 h in the dark, washed thrice, and then 
mounted with Vectashield mounting medium for fluorescence with DAPI (Vector 
Laboratories). The following primary antibodies were used: anti-Mdm2 IF2 (Ab-1, 
Calbiochem), anti-p53 1801/DO-1, anti-HA (16B12, Convance) or anti-FLAG (M2, 
Sigma). Images were taken on a Zeiss LSM 700 confocal microscope. 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR).  
RNA was isolated from cultured cells using the RNeasy Minikit (Qiagen), and 
then converted into cDNA using the QuantiTect reverse transcription kit (Qiagen). PCR 
was performed using the StepOne real-time PCR system with the power SYBR green 
PCR master mix (Applied Biosystems, Waltham, MA). Relative mRNA levels were 
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calculated by the ΔΔCT method (CT stands for threshold cycle), normalized against the 
levels of control L32 mRNA. 
 
Cytokinesis-block micronucleus assay.  
The cytokinesis-block micronucleus (CBMN) assay was performed with patient 
IV:7 and AG 1011 cells. 2.5 million cells were cultivated in 10 ml RPMI medium 
irradiated with 1 Gy or 2 Gy γ-rays using a Cs-137 source (Gammacell 2000, Nuclear 
Data, Frankfurt, Germany). After irradiation, cytochalasin B (CytB) was added to the 
cultures at a final concentration of 2 µg/ml. Cultures were harvested 41 h later by 
centrifugation, treated with a hypotonic solution (0.56% KCl) and fixed once with 
methanol/glacial acetic acid (5+1) mixed with an equal amount of 0.9% NaCl. Cells were 
then fixed three times with methanol/glacial acetic acid (5+1). Air-dried slides were 
stained with acridine orange (60 µg/ml in phosphate buffer). The frequency of 
micronucleated cells was determined by analysing 1000 binuclear cells from coded 
slides. Toxicity was measured using the nuclear division index (NDI) which was 
calculated from 500 cells according to the formula: NDI = (M1 + 2M2 + 3M3 + 4M4 
+5M5)/N, where M1 – M5 indicates the number of cells with one to five nuclei and N the 
total number of cells scored. 
 
Chromosome analysis.  
Exponentially growing LCLs were re-seeded into culture flasks at a density of 
2×105 /ml, left untreated for an additional 24 h or incubated with 80 ng/ml mitomycin C 
(MMC) for 48h. Cells were exposed to 100 ng/ml colcemid for 2 h, treated with 
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hypotonic solution (NaCl/sodium-citrate, 0.4 %) for 15 min and fixed with 3:1 
methanol/acetic acid. Slides were stained with Giemsa and 100 metaphase spreads 
were scored for chromosomal aberrations in two independent experiments. Metaphase 
spreads were observed using a Laborlux S microscope (Leitz, Germany) and captured 
using CytoVision® (Applied Imaging, USA). Data for chromosomal breaks in LCL´s 
were compared (untreated and MMC) using Poisson regressions with log link functions 
with the number of observed metaphases as an offset variable. LCL´s of AG1010 
served as the reference. P-values were not adjusted for multiple testing. P values, 
expressed as *P<0.05, **P<0.01 and ***P<0.001, were considered to be significant. 
 
Detection of senescence-associated β-galactosidase activity.  
Endogenous mammalian senescence-associated β-galactosidase activity (SAβ-
gal) was evaluated using the Senescence β-Galactosidase Staining Kit (Cell Signaling), 
according to the manufacturer’s guidelines. 
 
Zebrafish maintenance and manipulation.  
Wild-type Tupfel long fin (TL) zebrafish were maintained following standard 
protocols. 3 ng of Mdm2 RNA antisense morpholino oligonucleotides (MO) or 40pg of 
capped RNA, transcribed with the mMessage mMachine Kit (Ambion) from linearized 
plasmids, were injected into the blastodisc prior to the first cleavage. Embryos were 
kept at 28.5 ºC up to the tailbud stage (10hpf) and analyzed and processed as 
indicated. Concentrations of injected MO and RNA were calculated and volumes were 
adjusted in mineral oil for reproducible injection volumes prior to microinjections. RNA 
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quality was analyzed prior to injections by using 1.5% agarose gel electrophoresis. 
0,5% phenol red and 0,5% of rhodamine-dextrane were co-injected in order to monitor 
the equal distribution of the solution during injection. Six hours after injection embryos 
were sorted for homogeneity of the injected solution using a fluorescent stereoscope.  A 
previously established splice-site Mdm2 MO (5′-TGTTAAGAGATTCAGTACGCACCGC-
3′)(Parant et al., 2010) was used to generate loss-of-function zebrafish. Detection of 
apoptotic cells by TUNEL staining (terminal desoxynucleotidyl transferase-mediated 
biotinylated UTP nick end labeling) at 10hpf were performed using the In Situ Cell Death 
Detection Kit (Roche), as described before (Cole et al., 2001). 
 
Bioinformatic filtering of exome sequencing data 
 
Due to the parental consanguinity, we searched for a gene harbouring a very 
rare or unique homozygous variant with a severe impact on protein structure within the 
putative linkage regions. We excluded a possible pathogenicity of missense variants in 
TRIM45, CD48, PEX1, DGKA, INHBC and CACNA1G due to their low evolutionary 
conservation and the fact that they were predicted benign by Polyphen2 
(http://genetics.bwh.harvard.edu/pph2/index.shtml). Mutations in MYO1A were initially 
reported to cause an autosomal dominant form of hearing impairment a symptom which 
is not present in the index patient (Donaudy et al., 2003). Recently, the pathogenicity of 
heterozygous MYO1A mutations was challenged and it was demonstrated that even 
homozygous loss of function mutations in MYO1A do not cause any overt phenotype 
(Eisenberger et al., 2014) so that we also excluded the observed variant in this gene as 
potentially disease causing. MCM6, TIMELESS and BRCA1 are involved in the 
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maintenance of genomic stability and are thus predicted to lead to chromosomal 
instability if mutated, at least after treatment with replication-related stressors (Chanoux 
et al., 2009; Ishimi, 1997; Miyoshi et al., 2000). We therefore also excluded variants in 
these genes as we did not observe genomic instability in primary cell lines of index 
patient but rather the contrary, i.e. protection against chromosomal instability. In 
addition, the identified variants in BRCA1 seem to be rather common polymorphisms in 
Saudi Arabia (El-Harith el et al., 2002). GDE1 knock-out mice (MGI:1891827) are viable 
and do not display any overt abnormalities apart from reduced glycero-phospho-N-acyl 
ethanolamine (GP-NAE) phosphodiesterase activity in the brain. Moreover, these mice 
do not display any signs of premature aging (Simon et al., 2010). We therefore also 
excluded the possibility that the variant in GDE1 may add to the phenotype observed in 
the index patient. ARHGAP23 is a still uncharacterized, putative Rho GTPase activating 
protein of unknown function. Thus, we cannot fully exclude the possibility that the 
identified variant in this gene may contribute to the observed phenotype. However, the 
proven dysregulation of the Mdm2-p53 in patient cell lines and the additional functional 
data presented here strongly suggest that the anti-terminating MDM2 mutation is 
responsible for most, if not all of the phenotypes observed in the index patient. 




Statistical evaluation was performed depending on the experiment by either 
using 2-tailed Student´s test, Fisher's exact test or two-sample Poisson tests, as 
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specifically indicated for each experiment in figure legends. P values less than 0.05 
were considered significant. 
 
Data availability.  
All relevant data are available from the authors upon request. 
 
Study approval.  
The International Registry of Werner Syndrome has been recruiting patients 
suspected of Werner syndrome since 1988. The study has ongoing approval from the 
University of Washington Institutional Review Board. The study was performed in 





Characteristics of the studied patient.  
We studied a patient who was referred to the International Registry of Werner 
Syndrome (www.wernersyndrome.org) with the putative diagnosis of a Werner 
syndrome-like segmental progeroid disorder. The index patient (IV:7, Figure 2.1A and 
B), is the seventh child of unaffected, consanguineous parents of Saudi Arabian origin. 
At the age of 19 years, he presented with short stature (151cm), pinched facial features, 
premature grey hair, scleroderma-like skin changes, high pitched voice, hypogonadism, 
sparse pubic hair, small kidneys and consecutive kidney failure followed by severe 
arterial hypertension (Figure 2.1B and Table 2.1). Two of his sisters, IV:3 and IV:5, were 
reported to have had similar clinical features. In more detail, individual IV:3 had short 
stature, premature grey hair, hypertension, kidney failure, and died at the age of 31 
years from myocardial infarction. Individual IV:5 also had short stature and premature 
grey hair and suddenly died at the age of 23 years possibly from an epileptic attack. 
Their parents, III:1 and III:2, died at an unknown age of myocardial infarction and 
respiratory infection, respectively. No DNA from deceased individuals was available for 
genetic testing. Conventional Sanger sequencing revealed no mutation in known 
disease genes for progeroid syndromes (Lessel et al., 2015).  
 
Identification of the causative mutation.  
To unravel the cause of this disorder with suspected autosomal recessive 
inheritance, we first performed single-nucleotide polymorphism (SNP) array analysis. In 
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line with parental consanguinity, we identified 11 extended genomic regions of 
homozygosity with a maximum reachable LOD score (Figure 2.6). We then performed 
whole-exome sequencing in patient IV:7. Bioinformatic filtering identified only a single 
homozygous variant with severe impact on protein structure in the above-mentioned 
putatively linked genomic regions (Table 2.2), namely, a homozygous anti-terminating 
mutation, c.1492T>C, in MDM2. This mutation removes the physiological MDM2 stop 
codon and extends the protein for five further erroneous amino acids, p.*498Qext5 
(amino acids: QLTCL, Fig.1C). Previous cell-based transfection studies have shown 
that the highly conserved extreme C-terminus of Mdm2 is essential for its 
oligomerization and E3 ubiquitin ligase activity (Poyurovsky et al., 2007; Uldrijan et al., 
2007). In addition, a more recent study showed that the same MDM2 variant when 
ectopically expressed is unable to degrade co-expressed p53 in vitro (Dolezelova et al., 
2012).  
 
Regulation of cellular p53 levels.  
To corroborate our genetic findings, we analyzed p53 levels in primary dermal 
fibroblasts of patient IV:7. If compared to fibroblasts from healthy control individuals, we 
observed both elevated basal p53 protein levels and pronounced induction of p53 
protein in the patient’s fibroblasts after treatment with two well-studied p53 inducers, i.e. 
Nutlin-3, a small molecule inhibitor of the Mdm2-p53 interaction, and the anthracycline 
daunorubicin, a topoisomerase II-inhibitor (Figure 2.2A). Markedly elevated p53 and 
Mdm2 protein levels in lymphoblastoid cell lines (LCLs) from patient IV:7 as compared 
to LCLs from an unaffected individual confirmed these findings (Figure 2.S2A). Notably, 
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p53 activation by Nutlin-3 treatment suggests that mutant Mdm2 has residual p53 
degradation activity. Taken together, these data indicate a compromised Mdm2-p53 
negative-feedback loop as the likely pathogenic mechanism.  
Consistent with the study mentioned above (Dolezelova et al., 2012), we showed 
that ectopically expressed Mdm2 with the anti-terminating mutation is defective in its 
ability to degrade both ectopic and endogenous p53 in U2OS cells (Figures 2.S2B and 
C). In fact, expression of mutant Mdm2 led to increased levels of p53 protein in either 
case. Additionally, ectopic mutant Mdm2 accumulated to markedly higher levels than 
wild-type Mdm2 when introduced into U2OS cells or H1299 cells (a p53-null cell line), 
indicating that its increased stability is an intrinsic property of the protein itself and not a 
result of p53 transcriptional activity (Figure 2.S2D). When conditions were calibrated 
such that mutant Mdm2 and wild-type Mdm2 were expressed at equivalent levels, 
mutant Mdm2 still dramatically stabilized co-expressed p53 levels (Figure 2.S2E). 
These findings prompted us to further investigate Mdm2-p53 homeostasis in fibroblasts 
from patient IV:7. Inhibition of protein synthesis by cycloheximide (CHX) revealed that 
both Mdm2 and p53 were significantly stabilized in comparison to fibroblasts of an 
unaffected individual (Figure 2. S2B) and the relative stabilities of transiently co-
expressed mutant Mdm2 and p53 were also markedly pronounced compared with wild 
type Mdm2 and p53 (Figure 2. S2F). Further, inhibition of the proteasome by MG132 
confirmed the increased stability of p53 and Mdm2 in patient fibroblasts since their 
levels were just minimally increased after treatment as compared to fibroblasts of 
unaffected individuals (Figure 2.2C). Together, these data indicate that the identified 
mutation leads to impaired Mdm2 E3 ubiquitin ligase activity. This was confirmed by 
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transient transfection experiments showing that p53 co-expressed with mutant Mdm2 is 
under-ubiquitinated when compared to wild-type Mdm2 (Figure 2. S2G), and relatedly 
that MG132 treatment only very modestly increased ectopic p53 levels in the presence 
of mutant Mdm2 (Figure 2. S2H). Finally, immunocytochemistry revealed that untreated 
patient fibroblasts expressed relatively higher levels of nuclear p53, similar to fibroblasts 
of an unaffected individual treated with Nutlin-3 (Figure 2.2D). Transient transfection 
experiments again confirmed these observations showing that p53 was found both in 
the nucleus and cytoplasm when co-expressed with wild-type Mdm2 but was exclusively 
nuclear when co-expressed with mutant Mdm2 (Figure 2. S2I).   
In order to further analyze this mutation in a controlled background, we 
generated U2OS cell lines bearing one or two copies of mutant Mdm2, heterozygous 
and homozygous respectively, at its endogenous locus using transcription-activator-like 
effector nucleases (TALENs). It is noteworthy that despite the generation of multiple 
clones of other endogenous Mdm2 mutations (data not shown), we were only able to 
obtain a single homozygous clone expressing the anti-terminating MDM2 mutation, 
suggesting that cells expressing high levels of p53 could not be expanded during the 
selection process. In fact, basal and Nutlin-3 induced levels of p53 protein were similar 
among cells expressing WT/WT, WT/MUT and MUT/MUT Mdm2 (Figure 2.S3), 
indicating that the genome-edited MUT/MUT Mdm2 cells may have acquired a 
compensating mechanism to control basal p53 levels. To further determine the stability 
of mutant Mdm2 in the absence of complications due to presence of wild-type p53, we 
used CRISPR technology to generate p53 null versions in both parental and 
homozygous TALEN-generated cells (Figure 2.2E). Proteasome inhibition demonstrated 
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that the MUT/MUT Mdm2 cannot be further stabilized when p53 was knocked out, 
suggesting that it is inherently more stable than its wild-type counterpart. 
 
Cellular consequences of the MDM2 mutation.  
Since the primary sites of interaction between Mdm2 and p53 are within their 
respective N-termini, we expected the mutant Mdm2 to retain binding to p53. This was 
confirmed in patient LCLs (Figure 2.3A) and in cells ectopically expressing mutant 
Mdm2 and p53 (Figure 2.S4A). Therefore, it is likely that the mutant Mdm2 still retains 
its ability to repress p53 transcriptional transactivation ability through direct binding 
(Momand et al., 1992), potentially explaining why this mutation does not lead to 
embryonic lethality in humans. However, we repeatedly observed that p53 in patient’s 
cells can still be highly activated by treatments that release p53 from Mdm2 (Figure 
2.S5A), which lead to a pronounced induction of the RNA expression levels of p53 
target genes (p21, MDM2, NOXA, and PUMA) (Figure 2.3B). Notably, the mRNA 
induction of p53 target genes after Nutlin-3 was significantly higher as compared to cells 
treated with daunorubicin. It is well known that the dynamic behavior of p53 varies 
based on numerous factors such as duration of drug treatment, recovery period, and 
concentration of the drug used (Purvis et al., 2012). In this experiment, we used a 
specific time point (24h) to investigate whether p53 was activatable in patient 
fibroblasts. To investigate this further, we used different stressors, namely adriamycin, 
daunorubicin, mitomycin C (MMC), and aphidicolin, and analyzed protein expression 
after different (0, 4, 8, 24h) recovery periods. Indeed, each treatment resulted in 
enhanced and prolonged p53 protein levels with concomitant p53 serine 15 
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phosphorylation in patient fibroblasts (Figures 2.3C and 2.10). Additionally, with the 
caveat of working with a single homozygous clone, our data with genome-edited cells 
also showed that p53 is hyper-activatable after Nutlin-3 treatment, as evidenced by a 
much greater fold increase over basal RNA levels expressed from a set of p53 target 
genes (Figure 2.3D). Importantly as well, we found that basal expression of these p53 
targets is markedly lower in homozygous MUT/MUT cells than the parental cells, with 
mRNA expression in the heterozygous cells at intermediate levels (Figure 3D). 
Altogether, these data indicate that mutant Mdm2 is able to bind and repress the 
transcriptional activity of basal p53, but upon stress leads to p53 hyper-activation.   
These findings prompted us to perform chromosome breakage analysis and 
cytokinesis-block micronucleus (CBMN) assays, the latter of which enables 
simultaneous monitoring of genomic stability and cellular proliferation in LCLs under 
basal and stressed conditions. In contrast to many other segmental progeroid 
syndromes (Lessel et al., 2014), no genomic instability but rather a certain level of 
protection against ionizing radiation and MMC was observed in LCLs of the index 
patient, in accordance with the pronounced p53 stabilization after MMC treatment 
(Figures 2.4A and B). This protection, however, seemed to occur at the cost of cell 
viability, as calculated by the nuclear division index (NDI, Figure 2.4A), which is 
compatible with a decreased regenerative capacity and the development of signs of 
accelerated aging on an organismal level. Additionally, the patient fibroblasts had 
reduced replicative capacity and entered replicative senescence already at passage 28, 
whereas control fibroblasts stopped replicating at passage 43, comparable to the 
findings in other progeroid syndromes (Tivey et al., 2013). This was further confirmed by 
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senescence-associated beta-galactosidase staining (Figure 2.4C) and loss of LMNB1 
(Figure 2.4D).  
 
Impaired Mdm2 function in zebrafish.  
In order to confirm the significance of the identified MDM2 mutation on cellular 
outcomes at a physiological level in vivo, we finally utilized an established zebrafish 
model. As expected from previous work (Langheinrich et al., 2002), embryos either 
deficient in Mdm2 or overexpressing p53 displayed a severe apoptotic phenotype 
(Figure 2.5A). This phenotype could be rescued upon co-injection of wild-type MDM2 
mRNA, but not by an equimolar amount of mutant Mdm2 mRNA bearing an extension of 
the five amino acids identified in the index patient (Figures 2.5B and C). These findings 
confirm the evolutionary conserved role of the Mdm2 C-terminal tail and the pathogenic 






The human organism is under constant exposure to both endogenous and 
exogenous stressors, like oxidative stress, environmental toxic substances and 
ultraviolet light, to name only a few. If not dealt with, these threats can lead to DNA and 
cellular lesions that possess the potential to harm the organism and to limit survival. In 
order to cope with these pervasive threats, numerous cellular systems have evolved 
which sensitively detect stressors and initiate adequate cellular responses to limit 
potential damages. p53 plays an integrating and pivotal role in coordinating cellular 
reactions to stress signals, mainly by activating cell-cycle arrest, apoptosis or 
senescence (Vogelstein et al., 2000). The beneficial role of p53 as a tumour suppressor 
and the consequences of loss of p53 activity in human cancers have been intensively 
studied. It therefore seems logical that upregulation of p53 in principle appears to 
represent an attractive therapeutic approach and indeed numerous actual studies aim to 
identify drugs that specifically target the MDM2-p53 axis for cancer therapy. Moreover, 
first clinical trials for synthetic small molecules interfering with the MDM2-p53 interaction 
are already underway (Khoo et al., 2014; Q. Zhang et al., 2014). On the other hand, the 
potential effects of increased p53 activation on an organismal level in the human body 
are still unknown. It is therefore evident, that the detailed elucidation of possible 
consequences of p53 activation upon MDM2 inhibition on the human organism is of 
growing biomedical importance. 
In the context of mice, there have been conflicting reports linking p53 activity and 
aging. Two studies involving mice with N-terminal truncated p53 in the presence of 
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functional wild type p53 display accelerated aging phenotypes (Maier et al., 2004; Tyner 
et al., 2002). These mice appear to have aberrant Mdm2 regulation of p53 stemming 
from the truncation mutation and MEFs from both mouse models express normal p53 
protein levels but have constitutively active p53 (Moore et al., 2007). Yet super-p53 and 
hypomorphic MDM2 mice have no signs of early aging, while increased p53 activity may 
even delay the onset of aging (Garcia-Cao et al., 2002; Matheu et al., 2007; Mendrysa 
et al., 2006). p53 in these mice are normally regulated by Mdm2. Therefore, we 
speculate that either the ability of p53 to be hyper-activated, or its prolonged activation 
due to the impaired ability of the anti-terminating mutant Mdm2 in downregulating p53 
post-stress, might be critical factors contributing to the observed clinical phenotype. It is 
likely that certain p53 hyper-activated pathways are stressor-dependent and play 
differential roles in driving the aging phenotype. Thus, we hypothesize that in the index 
patient, these everyday stresses generate a chronic condition whereby pervasive and 
pronounced deleterious activation of p53 downstream targets induces a program of 
accelerated aging. Indeed, elevated levels of p53 with concomitant activation of p53 
pathway have been previously identified in several other segmental progeroid 
syndromes, eg. Ataxia–Telangiectasia, Hutchinson-Gilford progeroid syndrome and 
Cockayne syndrome (Latini et al., 2011; Liu et al., 2010; Varela et al., 2005). However 
we cannot completely exclude the possibility that p53-independent activities of Mdm2 
might also contribute to the observed phenotype (Li et al., 2013; Wade et al., 2010). Nor 
can we exclude the possibility that basally under-expressed p53 target genes in the 
patient and engineered cells are also contributing to one or more of the characteristics 




Engineered mice with diminished Mdm2 function may yield further insights into 
the Mdm2-p53 axis and aging. Mice null for Mdm2 expression or expressing a key 
Mdm2 RING domain mutation that abrogates E3 ligase activity (C462A) display an early 
embryonic lethal phenotype unless present in a p53 null background (Itahana et al., 
2007; Jones et al., 1995; Montes de Oca Luna et al., 1995). However, mice engineered 
with a mutation in the extreme C-terminus of Mdm2 (Y487A) that also affects RING-
RING interactions develop and age normally (Tollini et al., 2014). Although the extreme 
C-terminus of Mdm2 plays a critical role in RING-RING interactions required for its 
oligomerization and E3 ligase activity in human cells, co-expression of the Mdm2 
homologue MdmX at least partially rescues the E3 ligase defect of the C-terminal 
mutant Mdm2 (Dolezelova et al., 2012; Poyurovsky et al., 2007; Uldrijan et al., 2007). Of 
course, it is not a given that any genetic variant in mice will be phenocopied in humans, 
but we can speculate on a number of reasons for the Y487A mouse phenotype when 
compared to our IV:7 patient data. First, while we showed here that the Mdm2 anti-
termination mutation in human cells is more stable when either endogenously or 
exogenously expressed, the murine Y487A Mdm2 has comparable stability to wild-type 
Mdm2. Further, while we showed that basally p53 target genes are underexpressed in 
patient fibroblasts, p53 target genes are not underexpressed in mutant Y487A MEFs. 
Thus, the need for repressed basal p53 target gene expression could be a contributing 
factor to the premature aging phenotype, as basal p53 has been implicated in survival 
functions and regulation of longevity-associated process (Vousden et al., 2009). 
Alternately, the ability of p53 to be hyper-activated in the context of the mutant Mdm2 
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might be a critical factor contributing to the aging phenotype. Furthermore, It is well 
established that p53 can be induced by naturally occurring exogenous and endogenous 
stresses (Vousden et al., 2002). and exposure to certain sources of stress signals such 
as UV, ROS, etc. could be at play in promoting aging in a p53-dependent manner. 
Laboratory mice with related mutations would be spared exposure to many such 
stresses or other environmental stimuli which would be important co-factor(s) in the 
normal or pathological aging process.  
Indeed, p53 levels induced by everyday stresses and abnormally enhanced 
levels of autophagy, cell-cycle arrest, apoptosis, or senescence can ultimately cause 
tissue and organ dysfunction resulting in (premature) aging symptoms. One common 
characteristic in segmental progeroid syndromes is cellular senescence, one of the 
main hallmarks of “physiological” aging (Campisi, 2013; Lopez-Otin et al., 2013). 
Similarly, we observed premature senescence in patients’ fibroblasts. However, it is 
almost impossible to exactly define which of the numerous cellular pathways contribute 
to the various progeroid phenotypes as the functional response of p53 critically depends 
on cell-, tissue-, organ- and stress type. We also assume that the cellular consequences 
of the observed MDM2 mutation within different cell types and tissues may be different.  
In the presented family, idiopathic early-onset kidney failure followed by arterial 
hypertension and its predisposition to myocardial infarction seems to be the most 
malicious outcome at the organismal level. Intriguingly, in addition to being essential for 
maintenance of the nephron progenitor niche (Hilliard et al., 2014), studies in mice have 
suggested that the Mdm2-p53 axis specifically regulates kidney-specific cell healing and 
the response to inflammation (Mulay et al., 2012). Our data - even if based upon a 
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single patient – may indicate a potentially increased risk of side effects for systemic, 
long-term therapies with MDM2 inhibitors. Special emphasis to parameters of kidney 
function may therefore be advisable for clinical trials of synthetic small molecules 
interfering with the Mdm2-p53 interaction that are already underway. 
In summary, we identified a genetic cause of a segmental progeroid disorder and 
present direct evidence for a premature aging phenotype due to a functional 
disturbance of the p53-MDM2 axis in humans. We report on a patient who developed - 
at a rather early age - several symptoms that are typically observed in the elderly, 
compatible with the diagnosis of a segmental progeroid syndrome (Martin, 1978). 
Combining up-to-date genetic approaches including genome-wide linkage mapping and 
massively parallel sequencing, followed by in-depth functional characterization of 
patients’ primary cell lines and complementary in vitro and in vivo analyses, we 
identified a homozygous germline MDM2 mutation as the cause of his condition. 
Although we describe a single patient/family, the combination of (i) disease gene locus 
refinement by homozygosity mapping, (ii) the systematic analysis of all homozygous 
variants by exome sequencing, and especially (iii) the demonstration of altered 
regulation of and by p53 in cells from this specific patient, as evidenced by data from 
both in-vivo and ectopically expressed Mdm2 variants, fulfill previously proposed criteria 
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Figure 2.1. Identification of a causative mutation in MDM2 
(A) Pedigree of a consanguineous family (filled and open symbols denote affected and 
healthy individuals, respectively; an arrow indicates the index patient; diagonal lines 
indicate deceased status; the double line shows parental consanguinity). (B) Facial 
image of the index patient IV:7 at the age of 19 years. Note the short stature (151 cm on 
the scale), premature hair greying, pinched facial features with narrow nasal bridge and 
small mouth. (C) Sequence chromatogram shows c.1492T>C (p.*498Qext5) mutation 





Figure 2.2. The anti-terminating Mdm2 mutation is defective in its regulation of 
p53  
(A) Protein levels of Mdm2, p53, and actin in controls and IV:7 fibroblasts, treated with 
vehicle DMSO (-), Nutlin-3 (N, 10 μM), or daunorubicin (D, 0.1 mg/mL) for 24 hours. 
Left: Immunoblot (IB) with the indicated antibodies. Right: Fold change of basal p53 
levels over actin from five independent experiments.*p < 0.05 (Student’s T test) (B) 
Protein degradation rates of Mdm2 and p53 in fibroblasts via cycloheximide chase. Top: 
IBs of control#1 and IV:7 fibroblasts harvested at the indicated times (minutes) after 
cycloheximide (100 µg/ml) treatment. Bottom: Protein quantified, normalized to actin via 
ImageJ software and GraphPad Prism. Half-lives of Mdm2 (control#1: 62 min, IV:7: 92 
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min) and p53 (control#1: 45 min, IV:7: 82 min). (C) Effects of proteasome inhibition on 
levels of Mdm2 and p53. Left: IB of controls (3, 4, 1) and IV:7 fibroblasts, treated with 
vehicle (DMSO) or MG132 (25 μM) for 6 hours. Right: Protein quantified via ImageJ 
software, normalized to actin. Fold recovery calculated by comparing p53 or Mdm2 
values from treated to untreated cells. (D) Subcellular localization of Mdm2 and p53 in 
control#1 and IV:7 fibroblasts treated with vehicle (DMSO) or Nutlin-3 (10 μM) for 24 h. 
63X magnification. (E) U2OS genome edited cells expressing WT/WT and MUT/MUT 
Mdm2 with no p53 were treated with vehicle (DMSO) or the proteasome inhibitor 






Figure 2.3. The anti-terminating mutation results in abnormal p53 functional 
responses 
(A) Mdm2 and p53 can be co-immunoprecipitated. Proteins were harvested from control 
and IV:7 LCLs and detected after co-immunoprecipitation with anti-Mdm2 antibody (H-
221), and subsequent IB. All samples were run on the same gel. (B) Relative mRNA 
levels of p53 target genes after treatment with DMSO, Nutlin-3, and daunorubicin for 24 
hours in control#1 and IV:7 fibroblasts via qRT-PCR analysis. Bar graph is 
representative of 3 independent experiments and are not statistically significant. (C) 
Time course of p-p53, p53 and Mdm2 protein levels after treatment with Mitomycin C, 
Aphidicolin and Daunorubicin.  Shows protein levels of phospho(Ser15)-p53, p53 and 
Mdm2 of fibroblasts treated either with mitomycin C (left panel, MMC, 40 ng/mL), 
aphidicolin (middle panel, APH, 0.3 µM) or daunorubicin (right panel, Daunorubycin, 0.1 
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µM). Fibroblasts of control #1 (lanes 1-4) and IV:7 (lanes 5-8) were treated with for 24 
hours with indicated stressors. Cells were harvested either right after treatment (lines 1 
and 5), or were further cultured for 4 (lanes 2 and 6), 8 (lanes 3 and 7) or 24 hours 
(lanes 4 and 8) in stress free medium. Cell lysates were used for immunoblotting (IB) 
with phospho(Ser15)-p53 (Cell Signaling), p53 (AF1355), Mdm2 (N20) and anti-actin. 
(D) Relative mRNA levels of p53 target genes after treatment with DMSO and Nutlin-3 
for 24 hours in WT/WT, WT/MUT, and MUT/MUT U2OS genome edited cells via qRT-
PCR analysis. Bar graph is representative of 3 independent experiments. p < 0.05 for 






Figure 2.4. Functional consequences of the identified mutation in patient cells 
(A) Cytokinesis-block micronucleus (CBMN) assays in lymphoblastoid cell lines (LCLs). 
Effect of γ-irradiation (1 and 2 gray) on the induction of micronuclei (MN) in control and 
IV:7 (left axis), and on cell viability in the presence of cytochalasin B (CytB), indicated 
by the nuclear division index (NDI) (right axis).  Bar graphs summarize three 
independent experiments. NT: non-treated cells. (B) Chromosomal stability in LCLs. 
Shows the mean number of aberrations per cell observed in 100 metaphases of an 
unaffected individual (control LCL) and the index patient (IV:7 LCL).  LCL´s were left 
untreated or treated with 80 ng/ml of MMC (mitomycin C) for 48h. Bar graphs 
summarize two independent experiments. p-values are relative to control LCLs for each 
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treatment (n.s.-not significant, *P<0.05, two-sample Poisson tests). (C) Senescent 
phenotype of IV:7 fibroblasts. Control 1 and IV:7 fibroblasts at passage 28 were stained 
for β-galactosidase, and (D) protein levels of Lamin B1 and actin in primary fibroblasts 
of an unaffected individual (control 1) and the index patient, at the passage 18 (both), 





Figure 2.5. Impaired function of the anti-terminating Mdm2 mutation in a zebrafish 
model 
(A) Complementation assay in 10hpf zebrafish embryos (tailbud stage). (A) 
Representative images of the lateral view of 10 hpf zebrafish embryos stained by 
TUNEL assay. Embryos were classified by the number of positive TUNEL foci as 
follows: Class I (0-10), Class II (10-20), Class III (20-40) Class IV (>40). (B-C) 
Quantification of TUNEL foci/percentage of various apoptosis classes of embryos 
injected with 3ng of Mdm2 morpholino and co-injections of 40 pg of Mdm2 mRNAs and 
of embryos injected with p53 RNA and co-injections of 40 pg of Mdm2 mRNAs (right 
panel). NI: non-injected embryos, MO: embryos injected with Mdm2 morpholino, p53: 
embryos injected with p53 mRNA, +WT: co-injection of mdm2-wt, +MUT: co-injection of 
mdm2 bearing the anti-terminating mutation. Bar graphs summarize three independent 





Figure 2.S1. Genome-wide homozygosity mapping  
Shows the genome-wide homozygosity scores produced by HomozygosityMapper, 
using 867,266 selected SNP markers from the Affymetrix SNP Array 6.0. These are 
plotted against the physical position and as a bar chart with red bars indicating the most 
promising genomic regions. Note 13 extended genomic regions of maximal 





Figure 2.S2. Mutated Mdm2 is defective in its ability to regulate p53  
(A) Levels of Mdm2, p53, and actin in LCLs of an unaffected individual (lanes 1-3: 
control LCL) and index patient (lanes 4-6: IV:7 LCL). Cell lines were treated with vehicle 
112 
 
DMSO (-), Nutlin-3 (N, 10 μM), or daunorubicin (D, 0.1 mg/mL) for 24 hours before 
harvesting. Cell lysates were used for immunoblotting (IB) with the indicated antibodies 
(Mdm2: 2A9/3G5/4B11/5B10 mix, p53: MAbs 1801 and DO-1, anti-actin). (B) 
Degradation assay showing levels of ectopically expressed Mdm2 and p53 protein. 
U2OS cells were transfected with increasing amounts of constructs expressing N-
terminal FLAG-tagged wild-type (WT) and anti-termination mutant (MUT) Mdm2 as 
indicated (0.5-2 µg) and HA-tagged p53 (200 ng). Cells were harvested at 24 h. Cell 
lysates were used for immunoblotting (IB) with the indicated antibodies (Mdm2: FLAG; 
p53: HA, anti-actin). (C) Immunoblot showing levels of endogenously expressed p53 in 
presence of ectopically expressed WT or MUT Mdm2. U2OS cells were transfected with 
increasing amounts of N-terminal FLAG-tagged Mdm2 WT and MUT constructs as 
indicated (0.5-2 µg). Cells were harvested at 24h. A GFP construct (50ng) was included 
as a transfection and loading control. Cell lysates were used for immunoblotting (IB) 
with the indicated antibodies (Mdm2: FLAG, anti-actin, anti-GFP). (D) Levels of Mdm2 
protein in a p53-null cell line. H1299 p53-null cells were transfected with increasing 
amounts of FLAG-tagged Mdm2 WT and MUT constructs as indicated (0.5-2 µg) and 
harvested at 24h. A GFP construct (50ng) was included as a transfection and loading 
control. Cell lysates were used for IB with the indicated antibodies (Mdm2: FLAG, anti-
actin, anti-GFP). (E) Levels of ectopic p53 protein when WT and MUT Mdm2 proteins 
are expressed at similar levels. U2OS cells were transfected with N-terminal FLAG-
tagged Mdm2 constructs calibrated to express equivalent levels of empty vector (EV, 2 
µg), WT (2 μg) and MUT (0.4 μg) and HA-tagged p53 (200 ng) as indicated. Expression 
of GFP (50ng) was included as a transfection and loading control. (F) Protein 
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degradation rate of co-expressed Mdm2 and p53 via cycloheximide chase. U2OS cells 
were transfected with N-terminal FLAG-tagged Mdm2 WT and MUT constructs (2 µg) 
and HA-tagged p53 (200ng). 24 hours post-transfection, cells were treated with 100 
µg/ml cycloheximide and harvested at the indicated time points. A GFP construct (50 
ng) was included as a transfection and loading control. Cell lysates were used for 
immunoblotting with the indicated antibodies (Mdm2: FLAG, p53: HA, anti-GFP) and 
polypeptides were quantified using ImageJ software and normalized to GFP. Mdm2 and 
p53 half-lives were calculated through GraphPad Prism. (G) Shows relative 
ubiquitination of p53 by WT and MUT Mdm2 proteins. H1299 cells were transfected with 
constructs expressing N-terminal FLAG-tagged WT or MUT Mdm2 (2.6 μg), p53 
(260ng), and HA-tagged ubiquitin (866 ng). After 24 h, cells were treated with MG132 
(25 μM) for 4h before harvesting. Top panel: Aliquots of transfected cell lysates were 
subjected to immunoblotting with the indicated antibodies (Mdm2: FLAG, p53: FL-393, 
anti-GFP) to show input levels of the indicated proteins. Bottom panel: Extracts of cells 
were immunoprecipitated with anti-p53 antibodies (FL-393) and then probed with the 
anti-p53 polyclonal antibody (FL-393) to show higher molecular weight ubiquitinated p53 
polypeptides.  (H) Levels of ectopically-expressed Mdm2 and p53 after proteasome 
inhibition. U2OS cells were transfected with FLAG-tagged Mdm2 constructs calibrated 
to express equivalent levels of WT (2 μg) or MUT (0.4 μg) and HA-tagged p53 (200 ng). 
After 24 h, each set was either treated with MG132 (25 μM) for 4h or untreated with 
fresh media for 4h before harvesting. Left panel: Cell lysates were used for IB with the 
indicated antibodies. A GFP construct was included as a transfection and loading 
control. Right panel: Immunoblots were quantified using ImageJ software. Results 
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shown are average of three experiments. Differences in fold of Mdm2 and p53 
stabilization when WT or MUT Mdm2 was expressed has p < 0.05 significance. (I) 
shows the localization of ectopic p53 in cells expressing WT or MUT Mdm2. U2OS cells 
were transfected with N-terminal FLAG-tagged Mdm2 WT or MUT constructs (2 µg) and 
HA-tagged p53 (200 ng). Cells were fixed at 24 h and processed for 
immunofluorescence as described in Methods. The subcellular localization of p53 was 






Figure 2.S3. Mdm2 and p53 protein levels in U2OS genome-edited cells 
U2OS genome edited cells expressing WT/WT, WT/MUT, or MUT/MUT Mdm2 were 






Figure 2.S4. Ectopically expressed mutant Mdm2 retains binding to p53  
Shows that ectopic Mdm2 can bind to ectopic p53. U2OS cells were transfected with 
empty vector (EV, 2 µg) or N-terminal FLAG-tagged Mdm2 constructs calibrated to 
express equivalent levels of WT (2 µg) and MUT (0.35 µg) and harvested at 24 h. Left 
panel: Aliquots of transfected cell lysates were subjected to immunoblotting with the 
indicated antibodies (Mdm2: FLAG, p53: HA). Right panel: After co-immunoprecipitation 







Figure 2.S5. Time course of Mdm2, p53 and p21 protein levels after treatment with 
adriamycin  
Shows protein levels of Mdm2, p53 and p21 of fibroblasts treated with adriamycin (3 
μM). Control 88-1 (lanes 1-3) and IV:7 (lanes 4-6) fibroblasts were treated with 
adriamycin (3 μM)  for 24 hours. Cells were harvested either right after treatment (lines 
1 and 4), or were further cultured for 16 (lanes 2 and 5) or 24 hours (lanes 3 and 6) in 
adriamycin free medium. Cell lysates were used for immunoblotting (IB) with Mdm2 











Age at presentation 19 > 18 
Bilateral cataracts Absent +* 
Skin changes + +* 
Pinched nasal bridge + +* 




Parental consanguinity + +* 
Type 2 diabetes 
mellitus 
- + 
Hypogonadism + + 
Atherosclerosis - + 
Neoplasms - + 
High pitched voice + + 
Renal failure + - 
 
Table 2.1. Clinical findings in the index patient presented here and in Werner 
syndrome 
Skin changes include: scleroderma-like skin changes, tight, atrophic skin changes, 














TRIM45 1 c.466C>T His156Tyr rs139632476 0/79/115732 benign 
CD48 1 c.58T>C Ser20Pro rs375107070 0/5/121060 benign 
MCM6 2 c.2428T>C Tyr810His rs55660827 0/26/121342 
possibly 
damaging 
PEX1 7 c.627G>A Met209Ile rs200752969 0/19/111150 benign 
DGKA 12 c.512G>A Gly171Asp no no benign 
TIMELESS 12 c.2578C>T Arg860Cys no 0/1/121406 
probably 
damaging 
MYO1A 12 c.1361A>G Asp454Gly rs201562120 0/6/117630 
probably 
damaging 
INHBC 12 c.361G>A Asp121Asn rs201463741 0/5/121140 benign 
MDM2 12 c.1492T>C p.*498Qext5 no no - 
GDE1 16 c.242C>T Thr81Met no 0/1/107830 
probably 
damaging 
ARHGAP23 17 c.3047C>T Thr1016Met no 0/7/21948 
possibly 
damaging 
BRCA1 17 c.1648A>C Asn550His rs56012641 0/33/121032 
probably 
damaging 
BRCA1 17 c.1456T>C Phe486Leu rs55906931 0/36/121388 benign 
BRCA1 17 c.536A>G Tyr179Cys rs56187033 0/33/121410 
probably 
damaging 
CACNA1G 17 c.6710C>A Pro2237His rs200141555 0/60/117720 benign 
 
Table 2.2 Homozygous variants with minor allele frequencies (MAF) < 0.01 within 
regions of homozygosity  
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Mdm2 is an E3 ubiquitin ligase that is the primary negative regulator of p53. 
Mdm2 downregulates p53 activity through three mechanisms: targeted proteasome-
mediated degradation of p53, exportation of p53 from the nucleus, and direct inhibition 
of p53’s transactivation ability. Recently, a germline anti-terminating Mdm2 mutation 
was identified in a patient with an accelerated aging disorder. The resultant mutant 
Mdm2 protein has abrogated E3 ligase activity.  Here, we confirm that Mdm2 is 
impaired in regulating p53 in multiple tissue types. Genome-edited cells expressing 
mutant Mdm2 do not display Mdm2 and p53 hyper-stability, but exhibit dampened p53 
basal activity and hyper-activation, as evidenced by promoter binding and RNA 
expression upon p53 induction. In addition, MdmX plays an important role in mediating 
Mdm2 regulation of p53. MdmX is elevated in patient cells expressing mutant Mdm2. 
Inhibition of MdmX through siRNA depletion or treatment with a small molecule inhibitor 
leads to p53 elevation and enhanced cellular outcomes like cell cycle arrest and 
apoptosis. Altogether, our results suggest that MdmX can compensate for impaired 







Human aging pathologies often feature organ, tissue, and cellular degeneration 
(Campisi, 2013). At its nexus, aging stems from a gradual accumulation of DNA 
damage, leading to stem cell depletion, senescence, mitochondrial dysfunction, 
autophagy, etc. (Lopez-Otin et al., 2013). Many of these cellular characteristics are 
extensively regulated through multiple pathways, such as insulin/IGF-1, mTOR, and p53 
(Campisi, 2004). Significant crosstalk between pathways lead to multiple layers of 
regulation (Wiley et al., 2016). The p53 pathway can initiate prominent aging-related 
outcomes, including elevated senescence, increased reactive oxygen species (ROS) 
levels, altered cellular metabolism, diminished FOXO levels, and apoptosis-mediated 
stem cell depletion (Vousden et al., 2009). 
p53 is a sequence-dependent transcription factor that maintains genomic 
integrity and cellular homeostasis (Bieging et al., 2014). The p53 transcriptional 
program is modulated by a variety of stressors, leading to a myriad of tumor 
suppressive cell fates (Purvis et al., 2012).  Low levels of DNA damage induce 
temporary cellular arrest and repair mechanisms. However, acute or chronic stress can 
lead to elimination of the damaged cell or permanent withdrawal from the cell cycle, 
both of which can contribute to loss of healthy renewing cells in the tissues.  
Mouse models have implicated the role of p53 in human aging disorders. For 
example, mice modeling Hutchinson-Gilford progeria syndrome (HGPS) exhibit 
dramatic hair and skeletal changes at the physiological level, as well as aberrant 
nuclear architecture, upregulated p53 target genes, and premature senescence at the 
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cellular level (Varela et al., 2005). These findings were also validated in human HGPS 
fibroblasts, where replicative stress appears to be the key activator of p53-dependent 
senescence (Wheaton et al., 2017). Although mouse models do not recapitulate all 
developmental processes in humans, they do offer insights into how aberrant regulation 
manifest physiologically (Hasty et al., 2003; Poyurovsky et al., 2006).  Furthermore, they 
demonstrate that germline genetic variation can have tissue-specific expression and 
regulation (Hamard et al., 2013; Maniatis et al., 1987 ) 
p53 is tightly regulated by Mdm2 and MdmX. Mdm2 an E3 ubiquitin ligase that 
can downregulate p53 activity through degradation, nuclear export, and inhibition of p53 
transactivation. In addition, Mdm2 is itself a direct transcriptional target of p53, thereby 
forming an auto-regulatory feedback loop such that p53 and Mdm2 tightly regulate each 
other's cellular levels and activities (Barak et al., 1993; Wu et al., 1993). MdmX is a 
protein that can complex with Mdm2 to facilitate its E3 ligase activity (Linke et al., 2008; 
Tanimura et al., 1999). MdmX is cytoplasmic, unless induced to re-localize to the 
nucleus due to DNA damage and subsequent phosphorylation events (Li et al., 2002). 
In addition, MdmX overexpression inhibits oncogene-induced senescence through its 
binding (Miller et al., 2010). Due to structural homology to Mdm2, MdmX can also 
provide essential functions for Mdm2 when Mdm2 is impaired (Dolezelova et al., 2012; 
Uldrijan et al., 2007). 
In the previous chapter, we identified a novel homozygous germline mutation in 
Mdm2 in a patient (IV:7) with accelerated aging. This anti-terminating mutation in Mdm2 
(MUT) extends the C-terminus by 5 additional amino acids, QLTCL (Figure 3.1A). MUT 
Mdm2 is highly stable, defective as an E3 ubiquitin ligase, and is unable to regulate 
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Mdm2 and p53 levels. Thus, patient-derived dermal fibroblasts have elevated levels of 
p53 protein that accumulates in the nucleus in a heterogeneously manner. MUT Mdm2 
retains its ability to bind to p53 and can therefore inhibit p53 transactivation ability 
through direct binding. The aim of this chapter to extend these findings further. We 
examine if patient lymphoblastoid cell lines (LCLs) exhibit similar Mdm2/p53 activity in a 
separate tissue context, reaffirm genome-edited cell findings, investigate the role of 





Materials and methods 
 
Plasmids, siRNA, and transfection. 
FLAG and untagged wild type Mdm2 constructs were described previously. 
siRNAs used are from Qiagen (Valencia, CA, USA). siRNAs directed against luciferase, 
Mdm2 (siMdm2 #9, siMdm2 #10), and MdmX (siMdmX 102, siMdm4_4) were described 
previously (Biderman et al., 2012). DNA transfections carried out for 24 hours following 
the manufacturers instructions (Lipofectamine 2000, Thermo Fisher Scientific) before 
harvesting. siRNA transfections were carried out following the manufacturers 
instructions (Lipofectamine RNAiMAX, Thermo Fisher Scientific) for 48 hours before 
harvesting. 
 
Cell lines.  
Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) and 
primary dermal fibroblasts were established as previously described (Huang et al., 
2006). LCLs of previously used unaffected individual AG1010 (Lessel et al., 2015) were 
used as controls. Burkitt lymphomas AG876 and EW36 were generously provided from 
the lab of Riccardo Dalla-Favrera and also used as controls. Upon sequencing, AG876 
was revealed to have a homozygous R273C mutation in p53 and EW36 has a P72R 
SNP and a heterozygous M237V mutation.  LCLs were maintained in Roswell Park 
Memorial Institute (RPMI) medium supplemented with 10% fetal bovine serum. In 
experiments with primary dermal fibroblasts a previously used cell line of a healthy 
individual 82-6. Primary dermal fibroblasts from the patient (IV:7) and unaffected 
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individuals (82-6, NHDF, 1101SK, 88-6) were used as controls. Fibroblasts and U2OS 
osteosarcoma-derived cell lines were maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum. 
 
Genome edited cell lines.  
Two TALEN plasmids were designed to target nucleotides within the intron 
between exons 10 and 11 (taccttagacatagcaaa[G]ttgctagcattcctgtgactgagcagtta where 
[G] indicates a TALEN cutting site and the two TALEN binding sites are underlined 
bold), as recommended by ZiFiT Targeter software 
(http://zifit.partners.org/ZiFiT/TALZiFiTNuclease.aspx). A donor vector with two 1 kb 
homologous arms plus an FNF selection cassette (Frt-EM7- NeoR-Frt) was also 
constructed. The FNF selection cassette was inserted into the intron between exons 10 
and 11 of the mdm2 gene to facilitate clone selection as well as a unique HindIII site in 
exon 11. A T to C mutation was introduced into the donor vector at the stop codon TGA 
by site-directed mutagenesis. This results in an MDM2 variant with 5 amino acids 
extension. The donor and TALEN plasmids were transfected into U2OS cells followed 
by selection with G418 (800 μg/ml) for 2-3 weeks. The resistant clones were expanded 
and examined for FNF insertion on the mdm2 locus by PCR. The corrected clones were 
confirmed by sequencing to ensure that the allele carrying the mutation is corrected. 
Both heterozygous and homozygous clones were obtained. To serve as controls, 
isogenic wild-type clones were also obtained through the same selection process. 
Mutant Mdm2 p53 knockout cells were generated using CRISPR/Cas9 genome 
editing technology. Cells (7x105) were transfected with 2 μg p53 CRISPR/Cas9 KO 
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plasmid (Santa Cruz Biotech). Two days later, cells were treated with Nutlin-3 (10 μM) 
for 6 days to inhibit proliferation of cells with wild type p53, thereby enriching for p53 
knockout cells. Single cell clones were selected via limiting dilution, and p53 knockout 
clones were confirmed by Western blotting using FL-393 (Santa Cruz Biotechnology) 
rabbit polyclonal antibody. 
 
Immunoblotting.  
Cells were harvested with TEB lysis buffer (10 mM Tris-HCl pH 8, 1 mM EDTA, 
10% glycerol, 400 nM NaCl, 0.5% NP40 and supplemented with 50nM PMSF and 
protease inhibitor cocktail with 100 M Benzamidine, 300 g/L Leupeptin, 100 mg/ML 
Bacitracin, and 1 mg/mL a2-macroglobulin) and cleared by centrifugation 13,0000 rpm 
for 10 minutes at 4C. Protein concentration was measured using thåe Bio-Rad protein 
assay (Life Science Research, Hercules, CA). Equal amounts of total protein were 
resolved on 8% or 12% polyacrylamide gels (for ectopic or fibroblast/LCL work 
respectively), transferred to a nitrocellulose membrane, then blocked for 30 min in 
phosphate-buffered saline containing 0.1% Tween 20 (PBST) (Sigma-Aldrich, St. Louis, 
MO) and 5% nonfat dry milk. The membrane was incubated overnight at 4°C with 
primary antibodies in 1% milk PBST. Commercial primary antibodies used include anti-
FLAG (M2, Sigma), anti-HA (6B12, Covance), Mdm2 (N20 or H-221, Santa Cruz 
Biotechnology), p21 (C-19, Santa Cruz Biotechnology), anti-GFP (B2, Santa Cruz 
Biotechnology), and anti-actin (A2066, Sigma). Monoclonal antibodies used as in-house 
produced hybridoma supernatants include p53 (1801/DO-1) and Mdm2 (2A9, 3G5, 
4B11, and 5B10). After three washes with PBST, membranes were incubated with 
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secondary antibodies in 1% milk PBST for 30 min at room temperature. Secondary 
antibodies used included goat anti-mouse or goat anti-rabbit conjugated to horseradish 
peroxidase (Sigma) or fluorescent green goat-anti mouse, and fluorescent red donkey 
anti-rabbit (IRDye 800CW and IRDye 680LT, LI-COR Biosciences). Membranes were 
visualized either with ECL (GE Healthcare or Thermo Scientific) or the Odyssey Imaging 
System (LI-COR Biosciences). 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR).  
RNA was isolated from cultured cells using the RNeasy Minikit (Qiagen), and 
then converted into cDNA using the QuantiTect reverse transcription kit (Qiagen). PCR 
was performed using the StepOne real-time PCR system with the power SYBR green 
PCR master mix (Applied Biosystems, Waltham, MA). Relative mRNA levels were 
calculated by the ΔΔCT method (CT stands for threshold cycle), normalized against the 
levels of control L32 mRNA. 
 
Drugs.  
Drugs used were Nutlin-3 (a racemic mixture of the active Nutlin-3a and inactive 
Nutlin-3b, Sigma), cycloheximide (Calbiochem), MG132 (Calbiochem), daunorubicin 
(Sigma), 5-flurouracil and NSC207895 (Calbiochem). 
 
Immunofluorescence analyses.  
U2OS, control 1 and IV:7 primary fibroblasts were grown on coverslips in 35 mm 
petri dishes. Cells were washed twice with PBS and fixed with 4% paraformaldehyde 
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solution in PBS for 20 min at room temperature (RT). Following two additional washes, 
fixed cells were permeabilized with 0.5% Triton X-100 in PBS at RT for 1.5 min, washed 
twice, blocked with 0.5% bovine serum albumin in PBS for 30 min at RT, incubated with 
primary antibodies at RT for 1 h in blocking solution, washed thrice, incubated with a 
mixture of secondary antibodies conjugated with fluorescent dye (Alexa Fluor 488 and 
Alexa Fluor 594, Life Technologies) at RT for 1 h in the dark, washed thrice, and then 
mounted with Vectashield mounting medium for fluorescence with DAPI (Vector 
Laboratories). The following primary antibodies were used: anti-Mdm2 IF2 (Ab-1, 
Calbiochem), anti-p53 1801/DO-1, anti-HA (16B12, Convance) or anti-FLAG (M2, 
Sigma). Images were taken on a Zeiss LSM 700 confocal microscope. 
 
Detection of senescence-associated β-galactosidase activity.  
Endogenous mammalian senescence-associated β-galactosidase activity (SAβ-
gal) was evaluated using the Senescence β-Galactosidase Staining Kit (Cell Signaling), 
according to the manufacturer’s guidelines. 
 
Chromatin Immunoprecipitation (ChIP) 
 Chromatin immunoprecipitation was performed to detect p53 promoter binding. 
Cells were cross-linked in PBS containing 1% formaldehyde for 15 minutes and 
quenched with glycine (125 mM final concentration) for 5 min at RT. Cells were washed 
2X with cold PBS and harvested in PBS through scraping. Cell lysis was performed 
using RIPA buffer (50 mM Tris-HCl pH8, 5mM EDTA, 150 mM NaCl, 0.5% 
deoxycholate, 0.1% SDS, 1% NP-40 supplemented with protease inhibitors). DNA was 
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sheared by sonication (4X 30 seconds on, 30 seconds off, power level 1.5) and lysates 
cleared by centrifugation at 13,000 rpm for 15 minutes at 4C. Total protein 
concentration was measured using Bio-Rad Protein Assay and samples were 
normalized. Samples were then pre-cleared for 90 minutes with a mixture of protein A 
and protein G beads. Immunoprecipitation was performed overnight with mixed protein 
A/G beads (35 L) that were blocked at 4C with RIPA buffer with 1 mg/mL BSA and 0.3 
mg/mL salmon sperm DNA (Invitrogen). Beads were incubated for 2 hours with anti-p53 
1801/DO-1 hybridoma supernatant mixture or IgG and washed 2X with RIPA buffer, 4X 
Szak IP wash buffer, 2X RIPA buffer, and TE (70 mM Tris-HCl pH8, 1mM EDTA). 
Immunocomplexes were eluted by incubation in Tallandis Elution buffer (70 mM Tris-
HCl pH8, 1mM EDTA, 1.5% w/v SDS) for 10 minutes at 65C. Cross-linking was 
reversed by adding NaCl (final concentration 200 mM) and incubating at 65C for 5 
hours. DNA was purified using the QIAquick PCR purification kit (Qiagen). DNA was 
quantified with StepOnePlus Real-Time PCR system using Power SYBR Green PCR 
master mix (Applied Biosystems) and the Absolute Quantification method, in which 
ChIP DNA PCR reactions were run alongside a standard curve of genomic DNA. 
Regions amplified included the p53 response elements in the p21 promoter and a 
negative control site.  
 
Cell cycle analysis. 
 Cells were harvested by trypsinization, fixed overnight with 4°C ethanol. Fixed 
cells were spun down for 5 min at 2000 rpm, washed 3X with cold PBS, and re-
suspended in PBS containing RNase (50µg/ml) and propidium iodide (60 µg/ml, Sigma) 
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and incubated in the dark for 15 min at room temperature. Stained cells were analyzed 
in a fluorescence activated cell sorter (FACSCalibur, BD Biosciences) using the ModFit 





The anti-terminating mutant Mdm2 in patient lymphoblastoid cells is also hyper-stable. 
In order to confirm that our earlier findings of hyper-stable Mdm2 and p53 were 
not tissue specific, we examined patient LCLs in comparison to control LCLs. Once 
again, basal p53 protein levels were elevated in patient cells (Figure 3.1B). However, in 
contrast to patient fibroblasts, Mdm2 protein was also relatively more elevated. 
Interestingly, treatment with Nutlin-3, a small molecule inhibitor that disrupts the Mdm2-
p53 interaction, did not raise p53 protein levels in IV:7 LCLs, indicating that there is 
limited residual E3 ligase activity in this cell type (Figure 3.1B). Furthermore, the 
increased stability of p53 and Mdm2 in patient LCLs was confirmed by proteasome 
inhibition (Figure 3.1C) and cycloheximide chase experiments (Figure 3.1D). Finally, 
p53 activation by Nutlin-3 results in higher RNA expression of p53 target genes Mdm2, 
p21, Puma, Bax, Tigar, and Noxa (Figure 3.1E).  In LCLs however, no hyper-activation 
of target genes was observed, potentially due to the fact that Nutlin-3 did not raise 
levels of p53 protein in patient cells (Figures 3.1B and 3.S1A). Finally, treatment of 
patient cells with a range of genotoxic stressors (5-FU, cisplatin, etoposide) also had 
differential impacts on patient cells when compared to a diverse range of control cells 
(Figures 3.S1B and C). 
 
Genome edited cells bearing MUT display altered Mdm2-p53 activity.  
For a cleaner background, genome editing was employed to generate an 
isogenic series of cell lines that expressed one or two alleles of the anti-terminating 
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MUT Mdm2 at its endogenous locus. Utilizing TALEN and CRISPR/Cas9 technology, 
WT/WT, WT/MUT, MUT/MUT with wild type p53 and WT/WT p53 KO and MUT/MUT 
p53 KO where p53 was knocked out were generated. There were several differences in 
findings from patient versus U2OS-editted cells. Unlike in patient fibroblasts and LCLs, 
both basal and induced Mdm2 and p53 protein levels in MUT/MUT cells were 
comparable to levels in WT/WT cells (Figure 3.2A and 3.S2A). In addition, proteasome 
degradation stabilized both Mdm2 and p53 in WT/WT and MUT/MUT cells that harbored 
wild type p53 (Figure 3.2B). However, Mdm2 in three clones of MUT/MUT p53 KO cells 
remained low and could not be stabilized (Figure 3.2B). Independent of p53 status, 
MUT Mdm2 in genome-edited cells are not hyper-stable, as evidenced by 
cycloheximide chase experiments (Figures 3.2C and D).Furthermore, kinetic analysis of 
Mdm2 and p53 levels show limited differences between WT/WT and MUT/MUT 
response to p53 activating agents Nutlin-3 and daunorubicin (Figures 3.S2B and C). 
Finally, despite ectopic studies suggesting that WT Mdm2 can rescue C terminal 
extension Mdm2 mutants function towards p53 degradation (Dolezelova, 2012), ectopic 
expression of wild type Mdm2 was unable to rescue the E3 ligase activity of MUT Mdm2 
in WT/MUT and MUT/MUT cells (Fig 3.S2D). 
However, genome-edited cells share some commonalities in dysregulated p53 
activity as patient cells. MUT/MUT cells have dampened basal p53 activity that can be 
activated to transcribe of p53 target genes p21, Mdm2, Bax, and Tigar at a greater fold 
upon induction with Nutlin-3 and daunorubicin (Figure 3.2E). Consistent with this data, 
chromatin immunoprecipitation confirmed that p53 is less present at the p21 promoter 
under basal conditions, but recruited there at a greater level upon treatment with Nutlin-
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3 (Figure 3.2F). A downstream site (+11k) was used as a negative control. Cell cycle 
profile analysis showed that Nutlin-3 and Daunorubicin treatment led to S-phase and G-
1 drops, respectively in WT/WT and MUT/MUT cells (Figure 3.2G). Limited cell cycle 
profile changes were observed upon Nutlin-3 treatment in p53 KO lines, validating that 
Nutlin-3 effects on cell cycle are mostly p53-dependent (Figure 3.2G). However, 
induction of daunorubicin lead to a distinct G1 drop in p53 MUT/MUT KO cells, 
suggesting potent p53-independent mechanisms in these cells. (Figure 3.2G). 
 
The role of MdmX. 
 To investigate the role of MdmX in this accelerated aging phenotype, we first 
examined the levels of MdmX protein in patient primary cells. Interestingly, MdmX 
protein levels were slightly elevated in IV:7 patient LCLS and could interact with Mdm2 
(Figures 3.3A and B). When comparing the cell lines, MUT/MUT cells also expressed 
the greatest amount of MdmX protein (Figure 3.3C). Treatment with Nutlin-3 reduced 
the binding between Mdm2 and MdmX (Figure 3.S3A).  When MdmX was ablated via 
two different siRNAs, p53 and concordantly p21 protein in both WT/WT and MUT/MUT 
cells increased (Figure 3.3D). Mdm2 levels also increased upon MdmX knockdown 
(Figure 3.S2). Depletion of Mdm2 with two different siRNAs also raised p53 and MdmX 
protein levels (Figure 3.3E and 3.S3). In order to determine the effects of induction via 
p53-independent pathways, WTWT p53 KO and MUT/MUT p53 KO cells were treated 
with Nutlin-3 and daunorubicin, leading to no change and depletion of MdmX, 
respectively (Figure 3.3F). Finally, FACS was used to examine the cell cycle effects due 
to depletion of Mdm2 and MdmX in p53-dependent and p53-independent contexts. In 
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cells with wild type p53, cells transfected with siMdm2 and siMdmX displayed significant 
G1 arrest (Figure 3.3G). However, in p53 KO derivatives, Mdm2 and MdmX ablation 
had minimal effects on cell cycle profile (Figure 3.3H), indicating that Mdm2 and MdmX 
cell cycle effects are p53-dependent. 
 
Cells harboring MUT Mdm2 have altered morphology and are dependent on MdmX. 
 Microscopy was used to determine if cells harboring MUT Mdm2 displayed 
aging-related characteristics. Early passage IV:7 patient fibroblasts displayed altered 
morphology in comparison to early passage fibroblasts from three controls, 82-6, 88-1, 
88-6 (Figure 3.4A). Control fibroblasts displayed typical neatly-packaged spindle-
shaped morphology, while IV:7 fibroblasts were round and enlarged, almost senescent-
like (Rufini et al., 2013; Tchkonia et al., 2013). The patient fibroblasts became more 
elongated and clustered neatly two passages later, although their nuclei remained 
enlarged (Figure 3.4A). However, upon attempting to induce senescence with low 
dosage doxorubicin, SA-beta galactosidase staining revealed that despite the 
morphology, IV:7 fibroblasts are not senescent. DMSO-treated control fibroblasts, also 
stained for -galactosidase, suggesting that extended exposure to DMSO itself is toxic 
to normal fibroblasts; however, their morphology was consistent with the staining data 
(Figure 3.4B). 
 In order to investigate if MdmX inhibition would be detrimental to patient cells, 
control and IV:7 fibroblasts were treated with NSC207895, a small molecule inhibitor 
that suppresses MdmX promoter activity (Berkson et al., 2005; Wang et al., 2011). 
Treatment with increasing concentrations of NSC207895 resulted in significant p53 
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protein elevation, especially in IV:7 fibroblasts (Figure 3.4C). MdmX inhibition translated 
into cellular physiological consequences, as patient fibroblasts rapidly became enlarged 
and died (Figure 3.4D). Similar cell death was observed in genome-edited cells, 
although the differences between WT/WT, WT/MUT, and MUT/MUT response to the 
MdmX inhibitor were more subtle (Figure 3.4E). Altogether, these data implicate a major 





It is still unclear how Mdm2-mediated dysregulation of p53 can cause cells to 
acquire aging characteristics. New insights from isogenic genome-edited cells may 
provide clues. WT/MUT and MUT/MUT cells seem to have diminished levels of p53 
metabolic targets (Bax, Tigar) that can be hyper-activated upon Nutlin-3 induction or 
DNA damage activation. This could potentially tie in to the relationship between 
metabolism and aging (Wiley et al., 2016). As organisms age, mitochondrial dysfunction 
increases and respiration efficiency decreases (Kujoth et al., 2005). Part of the 
mitochondrial deterioration can be attributed to increased production of reactive oxygen 
species (ROS). However, simple elevation of ROS is insufficient to accelerate aging, 
and has in fact prolonged lifespan in yeast and C. elegans (Doonan et al., 2008). In 
contrast, defects in proofreading mtDNA enzymes have led to accelerated aging 
phenotypes in mice (Trifunovic et al., 2004).  
The p53 pathway often plays paradoxical roles in metabolism. While p53 is able 
to promote ROS production, p53 is also able to induce expression of anti-oxidant genes. 
Normal basal activity of p53 has been implicated in optimizing mitochondrial respiration 
and reducing ROS through SCO2, TIGAR, and sestrins (Vousden et. al, 2009, Bieging 
et. al, 2014). Therefore, analyzing the dampened basal p53 metabolic targets could 
pinpoint if mutant Mdm2 is promoting mitochondrial dysfunction in the patient. 
Multiple labs have demonstrated that deleting Mdm2 in mice result in embryonic 
lethal phenotypes that can only be rescued in a p53-null background, indicating the 
importance of restricting the apoptotic functions of p53 during initial development stages 
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(Jones et al., 1995; Montes de Oca Luna et al., 1995). The embryonic lethality 
phenotype of Mdm2C462A mice further confirm the necessity of Mdm2 E3 ligase function 
activity in this role (Itahana et al., 2007). However, Mdm2 in these mice are unable to 
bind to MdmX, indicating that any loss in function due to the C462A mutation cannot be 
compensated for by MdmX activity. In addition, MdmX null mice are also embryonic 
lethal, but the lethality occurs a few days later in development (Migliorini et al., 2002; 
Parant et al., 2001). Therefore, MdmX developmental defects are driven by alternative 
mechanisms than Mdm2 loss; likely though cell cycle arrest instead of apoptosis. 
Collectively, these studies suggest that Mdm2 and MdmX regulate p53 target gene 
specificity and distinct cellular outcomes. 
The viability of the patient demonstrates that mutant Mdm2 has lingering 
regulatory abilities towards p53. Therefore, we suggest that the anti-terminating mutant 
Mdm2 is able to inhibit the p53 apoptotic response. Also, the patient may have 
developed a reliance on MdmX to compensate for Mdm2 activity, as MdmX ablation 
through both transient siRNA expression and treatment with an MdmX inhibitor led 
cellular consequences of cell cycle arrest and cell death. Therefore, we speculate that 
impaired Mdm2 activity in the patient is partially combatted in two ways: 1) stable Mdm2 
is able to negatively regulate p53 through direct binding to prevent p53 transactivation 
and 2) increased levels of MdmX protein in patient cells may help restore p53 
degradation in patient cells.  
Several factors may contribute to each of these ideas. The Mdm2-p53 feedback 
loop leads to oscillations that are frequently stimuli-dependent (Lev Bar-Or et al., 2000; 
Purvis et al., 2012). Also, the kinetics of how Mdm2 interaction is disrupted and returned 
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to basal binding post-stress is poorly understood. In addition, ectopically expressed 
MdmX has been demonstrated to be able to rescue the E3 ligase activity of the QLTCL 
MUT Mdm2 (Dolezelova et al., 2012).  Therefore, enhanced MdmX expression could 
compensate for impaired Mdm2 to restrict p53 activity in the patient. As the ratio of 
MdmX:Mdm2 is important for proper function, elevated MdmX in patient cells could also 
potentially shift the stoichiometry in favor of p53 degradation (Gu et al., 2002). In 
addition, it is possible that other ubiquitin ligases that target p53 could be upregulated 
and aid p53 degradation post-stress (Love et al., 2012).  
Mdm2 participates in an auto-regulatory feedback loop and can target itself for 
proteasome-mediated degradation (Fang et al., 2000; Honda et al., 2000). The 
discrepancy between the cycloheximide and proteasome inhibition data suggest that 
Mdm2 is not fully stable in MUT/MUT cells, again perhaps due to MdmX. Alternatively, 
Mdm2 is not the only E3 ligase that can regulate Mdm2 turnover. In fact, proteins such 
as PCAF and Skp, Cullin, F-box containing complex SCF-TRCP have been shown to 
have ubiquitination activity towards Mdm2 and it is possible that these proteins are 
upregulated in MUT-bearing cells to maintain normal Mdm2 stability (Inuzuka et al., 
2010; Linares et al., 2007). 
Using TALEN and CRISPR/Cas9 edited cells to introduce the anti-terminating 
mutant Mdm2 resolves the major drawback of studying patient cells. In theory, the ideal 
controls for fibroblasts and genomic from a human patient are derived from the patient’s 
family – parents and unaffected siblings. Age-matching can also aid in quelling 
concerns about control samples. However, there is great variation in different cell lines 
due to human diversity. Indeed, when we screened 10 different fibroblast lines that 
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varied in tissue origin (lung and skin from arm or mid-abdomen biopsies), proliferative 
ability (primary and immortalized), and age (neonatal, 40-60 year old adults), we 
observed a wide spectrum of basal protein expression (data not shown). Interestingly, 
patient dermal fibroblasts always expressed higher levels of p53 protein than all other 
controls examined. In addition, there is potential that other mutations or SNPs have 
deleterious effects on the patient that could function synergistically with the 
dysregulated Mdm2-p53 axis to contribute to the aging phenotype. Due to these 
challenges, we turned to genome editing to introduce the mutant Mdm2 in a clean 
genetic background.  
Although genome editing allowed for replacement of Mdm2 at its endogenous 
locus to form isogenic clones, it did present challenges of its own. Due to selective 
pressures in a wild type p53 background, we were only able to obtain a single 
homozygous and two heterozygous clones expressing the anti-terminating Mdm2 
mutation, suggesting that cells expressing high levels of p53 could not be expanded 
during the selection process (data not shown). Attempts at eliminating p53 to generate 
MUT/MUT p53 knockouts were more successful and resulted in more clones, further 
validating the inhibitory role of wild type p53. Therefore, we cannot rule out any 
compensatory mutations in the MUT harboring cell lines, which may explain why p53 
protein levels in WT/MUT and MUT/MUT were comparable to wild type parental cells. 
Finally, U2OS cells offer multiple advantages: they are easily transfectable, proliferate 
rapidly, and are immortal. Although immortal cells aid in the single clone selection 
process, they may also be unable to succumb to aging-related pathways, particularly 
those driven by telomere dysfunction. In addition, U2OS cells lack p16/p19, which may 
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hinder regulation of Mdm2 and senescence pathways, making the cells more resilient 
even upon exposure to damaging stimuli (Al-Mohanna et al., 2004). Despite these 
drawbacks, the cells are still valuable and yielded interesting insights into the functional 
properties of Mdm2. In summary, our data suggest that the anti-terminating mutant 
Mdm2 has tissue-specific effects and that MdmX could play an important role in 
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Figure 3.1. MUT Mdm2 functional properties are recapitulated in patient LCLs 
(A) Schematic of WT Mdm2 compared to MUT Mdm2. MUT Mdm2 has an abolished 
stop codon, leading to a C-terminal extension of Mdm2 by 5 amino acids. (B) Protein 
levels of Mdm2, p53, and actin in AG1010 and IV:7 LCLs, treated with vehicle DMSO (-
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), Nutlin-3 (N, 10 μM), or daunorubicin (D, 0.1 mg/mL) for 24 hours (C) Effects of 
proteasome inhibition on levels of Mdm2 and p53. Control AG1010 and patient IV:7 
LCLs were treated with vehicle (DMSO) or MG132 (25 μM) for 6 hours before harvest 
and IB. (D) Protein degradation rates of Mdm2 and p53 in LCLs via cycloheximide 
chase. AG1010 and IV:7 LCLs were harvested at the indicated times (minutes) after 
cycloheximide (100 µg/ml) treatment and used for IB. (E) Relative mRNA levels of p53 
target genes after treatment with DMSO or Nutlin-3 for 24 hours in AG1010 and IV:7 





















Figure 3.2. MUT Mdm2 in genome-edited cells is not stable, but can dysregulate 
p53 activity. 
(A) Protein levels of Mdm2, p53, p21, and actin in WT/WT, WT/MUT, and MUT/MUT 
cells. Cells were treated with DMSO (-), Nutlin-3 (N, 10 μM), or daunorubicin (D, 0.1 
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mg/mL) for 24 hours before harvest and IB with the indicated antibodies. (B) Effects of 
proteasome inhibition on Mdm2 and p53 protein levels. WT/WT (lanes 1-2), MUT/MUT 
(lanes 3-4), WT/WT p53 KO (lanes 5-6), and 3 clones of MUT/MUT p53 KO (lanes 7-12) 
cells were treated with vehicle (DMSO) or the proteasome inhibitor MG132 (25 μM) for 6 
hours before harvest and IB. (C) Protein degradation rates of Mdm2 and p53. WT/WT 
and MUT/MUT cells were treated with cycloheximide (100 µg/ml) and harvested at the 
indicated time points (minutes). (D) Protein degradation rates of Mdm2 in p53 knockout 
cell lines. WT/WT p53 KO and a pool of MUT/MUT p53 KO pool of cells were treated 
with cycloheximide (100 µg/ml) and harvested at the indicated time points (minutes). (E) 
Relative mRNA levels of p53 target genes. WT/WT, WT/MUT, and MUT/MUT cells were 
treated with DMSO (-), Nutlin-3 (N, 10 μM), or daunorubicin (D, 0.1 mg/mL) for 24 
hours. Relative mRNA levels of Mdm2, p21, Bax, Tigar were examined via qRT-PCR 
analysis. (F) p53 binding to p21 promoter. WT/WT and MUT/MUT cells were treated 
with DMSO (-), Nutlin-3 (N, 10 μM), or daunorubicin (D, 0.1 mg/mL) before collection for 
ChIP as described. p53 antibody used was 1801/DO-1. Regions amplified included the 
p53 response elements in the p21 promoter and a negative control site (+11K). (G) Cell 
cycle profile analysis. WT/WT, WT/WT p53KO, MUT/MUT, MUT/MUT p53 KO were 
treated with DMSO , Nutlin-3 (10 μM), or daunorubicin (0.1 mg/mL) for 24 hours before 














Figure 3.3. MdmX may restore Mdm2 function 
(A) Protein levels of Mdm2, p53, and actin in EW36, AG876, and IV:7 LCLs. (B) MdmX 
can co-immunoprecipitate with Mdm2 in AG1010 and IV:7 LCLs. Input Mdm2, p53, and 
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actin protein level. Lysates were probed with anti-Mdm2 antibody and detected with 
MdmX antibody. (C) Protein levels of Mdm2, p53, and actin in genome-edited cell lines. 
Three different WT/WT clones (lanes1-3), WT/WT p53KO (lane 4), MUT/MUT (lane 5), 
MUT/MUT p53 KO (lane6), and WT/MUT (lane 7) were harvested at confluency and 
used for IB. (D) Effects of ablation of MdmX on p53 and p21 protein levels. WT/WT 
(lanes 1-3), MUT/MUT (lanes 4-6), WT/WT p53KO (lanes 7-9), MUT/MUT p53 KO 
(lanes 10-12) were transfected with siRNAs against luciferase or MdmX for 48 hours 
before harvest and IB with the indicated antibodies. siLuciferase (L), siMdm4_4 (4), and 
siMdmX 102 (X) were used. (E) Effects of ablation of Mdm2 on MdmX and p53 protein 
levels. Two WT/WT clones (lanes 1-6), WT/MUT (lanes 7-9), MUT/MUT (lanes 10-12) 
were transfected with siRNAs against luciferase or Mdm2 for 48 hours before harvest 
and IB with the indicated antibodies. siLuciferase (L), siMdm2 #9 (9), and siMdm2 #10 
(10) were used. (F) MdmX levels after induction in p53 knockout cells. WT/WT p53KO 
and two MUT/MUT p53 KO cell lines were treated with DMSO (-), Nutlin-3 (N, 10 μM), 
or daunorubicin (D, 0.1 mg/mL) for 24 h and harvested for IB. (G) Effects of Mdm2 and 
MdmX ablation on cell cycle. WT/WT and MUT/MUT cells were transfected with siRNAs 
against luciferase, Mdm2, or MdmX for 48 hours before fixing for FACS. siRNAs used 
were siLuciferase (siLuc), siMdm2#9, and siMdmX 102. ModFit LT software program 
was used for analysis. (H) Effects of Mdm2 and MdmX ablation on cell cycle in p53 
knockout lines. WT/WT p53KO and MUT/MUT p53 KO cells were transfected with 
siRNAs against luciferase, Mdm2, or MdmX for 48 hours before fixing for FACS. siRNAs 
used were siLuciferase (siLuc), siMdm2#9, and siMdmX 102. ModFit LT software 




















Figure 3.4. MUT-harboring cells exhibit physiological alterations 
(A) Morphology of fibroblasts. Light microscopy was used to capture photographs of 
three control fibroblasts (82-6, passage 11; 88-1, passage 7; and 88-6, passage 7) and 
patient IV:7 fibroblasts (passage 5 and 7) grown at confluency.  (B) Senescence and 
morphology of fibroblasts. 82-6 and patient IV:7 fibroblasts were grown to near 
confluency before treatment with DMSO, 100 nM doxorubicin, or 1 μM doxorubicin for 
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24 hours. Fresh media replenished the cells for 4 days before fixing for senescence-
associate beta galactosidase staining. (C) Protein levels of p53 after MdmX inhibition. 
Primary 82-6, 88-6, and IV:7 fibroblasts were treated with DMSO or the MdmX inhibitor 
NSC207598 at increasing concentrations (2.5, 5, and 10 μM) for 24 hours before 
harvest and IB. (D) Fibroblast morphology after MdmX inhibition. Primary 82-6, 88-6, 
and IV:7 fibroblasts were treated with DMSO or the MdmX inhibitor NSC207598 at 
increasing concentrations (INH; 2.5, 5, and 10 μM) for 24 hours before light microscopy 
was used to capture the photographs. (E) Cell morphology after MdmX inhibition. 
WT/WT, WT/MUT, and MUT/MUT genome edited cells were treated with DMSO or 10 
μM of the MdmX inhibitor NSC207598 (INH) for 24 hours before light microscopy was 






























Figure 3.S1. Patient cell responses to genotoxic stressors 
(A) Protein levels of Mdm2, p53, and actin in control 82-6, NHDF, 1101SK, and patient 
IV:7 fibroblasts, treated with vehicle DMSO (-), Nutlin-3 (N, 10 μM), daunorubicin (D, 0.1 
mg/mL), or fluorouracil (F) for 24 hours (B) Protein levels of Mdm2, p53, p21 and actin 
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in AG876, EW36, and IV:7 LCLs, treated with vehicle DMSO (-), Nutlin-3 (N, 10 μM), or 
cisplatin for 6 hours. EW36 was not treated with cisplatin. (C) Protein levels of Mdm2, 
p53, and actin in AG876 and IV:7 LCLs, treated with vehicle DMSO (-), etoposide (E, 10 
























Figure 3.S2. Characterization of genome-edited cells 
(A) Subcellular localization of Mdm2 and p53 in WT/WT, WT/MUT, MUT/MUT treated 
with vehicle (DMSO) or Nutlin-3 (10 μM) for 24 h. (B) Protein levels of Mdm2, p53, actin, 
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and p21 at 0-48 hour time points. WT/WT and MUT/MUT cells were treated with Nutlin-
3 (10 μM),or (C) daunorubicin (0.1 mg/mL) for the indicated time points (hours) before 
harvest and IB. (D) Protein levels of Mdm2, p53, actin, and GFP upon ectopic wild type 
Mdm2 expression. WT/WT, WT/MUT, and MUT/MUT cells were transfected with 2μg of 
empty vector pCDNA3 (1), FLAG-tagged Mdm2 (2) or untagged Mdm2 (3) for 24 hours 






















Figure 3.S3. Mdm2 and MdmX interplay 
(A) Mdm2 does not bind to MdmX upon nutlin-3 treatment. U2OS genome edited cells 
expressing WT/WT, WT/MUT, or MUT/MUT Mdm2 were treated with DMSO or Nutlin-3 
(10 μM) for 24 hours co-immunoprecipitation with anti-Mdm2 antibody (H-221), and 
subsequent IB. (B) Effects of ablation of Mdm2/MdmX on Mdm2 and p53 protein levels. 
WT/WT (lanes 1-5) and MUT/MUT (lanes 7-11), were transfected with siRNAs against 
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luciferase or MdmX for 48 hours before harvest and IB with the indicated antibodies. 
siLuciferase (L), siMdm2 #9 (9), and siMdm2 #10 (10), siMdmX 102 (X) and siMdm4_4 
(4) were used. (C) Effects of ablation of Mdm2/MdmX. WT/WT (lanes 1-5) and 
MUT/MUT (lanes 6-10), were transfected with siRNAs against luciferase or MdmX for 
48 hours before harvest and IB with the indicated antibodies. siLuciferase (L), siMdm2 
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Although the roles of p53 as a tumor suppressor have been extremely well 
studied, the relationship between p53 and other diseases remains elusive. The Mdm2 
E3 ubiquitin ligase is the primary negative regulator of p53. Mdm2 acts through three 
mechanisms: targeted proteasome-mediated degradation of p53, exportation of p53 
from the nucleus, and inhibition of p53’s transactivation ability. Recently, a 
heterozygous germline Mdm2 mutation were identified in two patients presenting with 
segmental progeria. The mutation leads to alternative splicing of two isoforms: a single 
point mutation in the p53 binding domain and deletion of 25 amino acids in the p53 
binding domain. Our results show that the latter, likely causative Mdm2 variant in this 
patient can enhance both p53 and Mdm2 stabilization. In line with this, in vivo 
ubiquitination assays indicate that the ability of this Mdm2 variant to bind to p53 and 
target p53 for proteasome-mediated degradation is impaired. Together, our results 
suggest that defective Mdm2 leading to increased p53 accumulation can be found in 






p53 is an important transcription factor that regulates a variety of cellular 
outcomes, including cell cycle progression, apoptosis, senescence, autophagy, genomic 
stability, stem cell depletion, and cellular metabolism (Vousden et al., 2009). Upon 
exposure to genotoxic damage and physiological stressors, p53 can mediate tumor 
suppression. Several lines of evidence demonstrate that inactivation of p53 can lead to 
tumorigenesis. Families with Li-Fraumeni syndrome have high predispositions for 
cancer and heterozygous hereditary p53 mutations (Malkin et al., 1990; Srivastava et 
al., 1990). Engineered mice that have one or both alleles of p53 deleted develop 
normally, but are predisposed for tumor development, specifically lymphomas and 
sarcomas (Donehower et al., 2009). Additionally, inactivating somatic TP53 mutations 
have been identified in the majority of human tumors (Vogelstein, 1990; Vogelstein et 
al., 2000). Although the roles of p53 as a tumor suppressor have been well 
characterized, the relationship between the p53 pathway and aging has not yet been 
elucidated. 
Under basal conditions, p53 is maintained at low cellular levels. In response to 
damage, p53 is rapidly stabilized. Maintenance and regulation of p53 is mostly 
attributable to the function of the E3 ubiquitin ligase Mdm2, which controls cellular p53 
levels and activity through at least three mechanisms: (i) direct binding and blockage of 
p53 transactivation ability, (ii) mono-ubiquitination leading to export of p53 out of the 
nucleus, and (iii) poly-ubiquitination leading to 26s proteasome-mediated degradation of 
p53 (Iwakuma et al., 2003; Leslie et al., 2016). Mdm2 is itself a direct transcriptional 
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target of p53, thereby forming a negative feedback loop such that p53 and Mdm2 tightly 
regulate each other's cellular levels and activities (Wade et al., 2010).  
Two patients (BRA90250 and BRA90251) were recently identified who presented 
with symptoms similar to a form of late-onset adult progeria, atypical Werner’s 
Syndrome, including gray hair, cataracts, and early skin wrinkling (Table 4.1, Figure 
4.1A). The mother-son pair did not have mutations in the canonical Werner’s Syndrome 
associated gene WRN (Hasty et al., 2003). WRN is a RecQ DNA helicase involved in 
DNA damage repair, particularly double-stranded breaks and has also been linked with 
maintenance of telomeres (Ahn et al., 2004; Crabbe et al., 2004). Through sequencing 
of the atypical WS patients’ genomes, no mutations in other progeria-associated genes, 
including LMNA, and ZMPSTE were discovered (Navarro et al., 2006). However, these 
patients do have germlines mutations in DNA Polymerase Delta 1 (POLD1), a protein 
family of polymerases that also have 3’ to 5’ exonuclease activity. The POLD1 is likely 
to be the causative mutation of the accelerated aging phenotype observed in these 
patients (Lessel et al., 2015). POLD1 is critical for genomic stability and cell cycle 
progression, and defects in POLD1 have both oncogenic and aging implications 
(Nicolas et al., 2016; Palles et al., 2013; Song et al., 2015). POLD1 has also been 
shown to be capable of binding to WRN (Kamath-Loeb et al., 2000; Szekely et al., 
2000).  Additionally, POLD1 appears to be a potential repressive target of p53 and 
could therefore be a downstream effector of p53 in aging (Li et al., 2001).  
Intriguingly, the patients also have a heterozygous mutation in Mdm2. Both 
patients share the same heterozygous nucleotide alteration in the p53-binding domain 
of Mdm2. This point mutation yields two alternative isoforms of Mdm2: BRA – a V28F 
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point mutation, and BRA-DEL – a 25 amino acid deletion (exon 4 of Mdm2) (Figure 
4.1B-C). Notably, because the Mdm2 mutation is heterozygous, these patients do carry 
one wild type allele of Mdm2 as well. Thus, it is necessary to consider if dominant 
negative or gain of function mechanisms for these Mdm2 variants could contribute to 
the aging phenotype. 
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Materials and methods 
 
Cell lines.  
Human osteosarcoma (U2OS) and non-small cell lung cancer (H1299) cell lines 
were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal 
bovine serum. Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) 
were established as previously described. Burkitt lymphomas AG876 and EW36 were 
generously provided from the lab of Riccardo Dalla-Favrera and used as controls. Upon 
sequencing, AG876 was revealed to have a homozygous R273C mutation in p53 and 
EW36 has a P72R SNP and a heterozygous M237V mutation. Burkitt lymphomas and 
patient LCLs were maintained in Roswell Park Memorial Institute (RPMI) medium 
supplemented with 10% fetal bovine serum.  
 
Plasmids. 
 Full-length human MDM2 cDNA´s were cloned into pCS2+ and pcDNA3.1 
(Invitrogen), respectively. Mutants were cloned using PCR amplification and restriction 
enzyme digestion and recombination. Site-directed mutagenesis was performed by 
PCR to introduce desired mutations. The correctness of the DNA sequence was verified 
by sequencing. Constructs made included N-terminal tagged Mdm2 WT, MUT, BRA, 







Drugs used were Nutlin-3 (a racemic mixture of the active Nutlin-3a and inactive 
Nutlin-3b, Sigma), cycloheximide (Calbiochem), MG132 (Calbiochem), cisplatin 
(Sigma), etoposide (Sigma), and doxorubicin (Sigma).  
 
Immunoblotting.  
Whole cell lysates were analyzed by standard immunoblotting procedure. Protein 
concentration was measured using the Bio-Rad protein assay (Life Science Research, 
Hercules, CA). Equal amounts of total protein were resolved on 8% or 12% 
polyacrylamide gels (for ectopic or fibroblast/LCL work respectively), transferred to a 
nitrocellulose membrane, then blocked for 30 min in phosphate-buffered saline 
containing 0.1% Tween 20 (PBST) (Sigma-Aldrich, St. Louis, MO) and 5% nonfat dry 
milk. The membrane was incubated overnight at 4°C with primary antibodies in 1% milk 
PBST. Commercial primary antibodies used include anti-FLAG (M2, Sigma), anti-HA 
(6B12, Covance), p53 (AF1355, R&D systems), Mdm2 (N20 or H-221, Santa Cruz 
Biotechnology), p21 (C-19, Santa Cruz Biotechnology), anti-GFP (B2, Santa Cruz 
Biotechnology), and anti-actin (A2066, Sigma). Monoclonal antibodies used as in-house 
produced hybridoma supernatants include p53 (1801/DO-1) and Mdm2 (2A9, 3G5, 
4B11, and 5B10). After three washes with PBST, membranes were incubated with 
secondary antibodies in 1% milk PBST for 30 min at room temperature. Secondary 
antibodies used included goat anti-mouse or goat anti-rabbit conjugated to horseradish 
peroxidase (Sigma) or fluorescent green goat-anti mouse, and fluorescent red donkey 
anti-rabbit (IRDye 800CW and IRDye 680LT, LI-COR Biosciences). Membranes were 
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visualized either with ECL (GE Healthcare or Thermo Scientific) or the Odyssey Imaging 
System (LI-COR Biosciences). 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR).  
RNA was isolated from cultured cells using the RNeasy Minikit (Qiagen), and 
then converted into cDNA using the QuantiTect reverse transcription kit (Qiagen). PCR 
was performed using the StepOne real-time PCR system with the power SYBR green 
PCR master mix (Applied Biosystems, Waltham, MA). Relative mRNA levels were 
calculated by the ΔΔCT method (CT stands for threshold cycle), normalized against the 
levels of control L32 mRNA. 
 
Study approval.  
The International Registry of Werner Syndrome has been recruiting patients 
suspected of Werner syndrome since 1988. The study has ongoing approval from the 
University of Washington Institutional Review Board. The study was performed in 





Mdm2 variants differ in protein levels and ability to degrade or interact with p53. 
In order to assess the functional properties of each individual Mdm2 variant, FLAG-
tagged Mdm2 constructs bearing the point mutation V28F BRA and the 25 amino acid 
deletion BRA-DEL were generated and compared to wild type (WT) Mdm2 and an anti-
terminating mutant Mdm2 (MUT) that is defective as an E3 ligase (discussed in 
chapters two and three). Ectopically expressed Mdm2 differed in their abilities to 
regulate Mdm2 protein levels. While BRA-DEL is defective in its ability to degrade both 
ectopic and endogenous p53 in U2OS cells, BRA is hyperactive in its ability to degrade 
p53 (Figure 4.2A-B). In addition, expression of BRA-DEL, but not BRA Mdm2 led to 
increased accumulation of Mdm2 protein when introduced into p53-WT U2OS cells or 
p53-null H1299 cells (Figure 4.2C). These data indicate that BRA-DEL Mdm2 is more 
stable than WT and BRA, but not as stable as E3-defective MUT Mdm2. In addition, this 
increased stability in BRA-DEL is not dependent on p53 transcriptional activity. When 
conditions were calibrated such that mutant Mdm2 and wild-type Mdm2 were expressed 
at equivalent levels at the protein level, it revealed that less BRA-DEL mRNA was 
necessary to produce the equivalent level of Mdm2 protein (Figure 4.2D). Furthermore, 
co-immunoprecipitation of ectopic Mdm2 and p53 demonstrated that BRA-DEL Mdm2 is 
impaired in its ability to bind to p53 (Figure 4.2E), suggesting that the BRA-DEL protein 






Mdm2 BRA-DEL variant is stable and cannot regulate p53 
Inhibition of protein synthesis by cycloheximide (CHX) revealed that transiently 
expressed BRA-DEL Mdm2 and co-expressed p53 is markedly more stable compared 
to WT and BRA Mdm2 and p53 (Figure 4.3A). Notably, BRA-DEL is not as stable as the 
E3 ligase-defective MUT Mdm2. Furthermore, inhibition of the proteasome by MG132 
confirmed the increased stability of p53 and Mdm2 when BRA-DEL was transiently 
expressed (Figure 4.3B). Transient transfection experiments also showed that p53 co-
expressed with either MUT and BRA-DEL Mdm2 is under-ubiquitinated when compared 
to p53 co-expressed with WT and BRA Mdm2 (Figure 4.3C). To establish if BRA-DEL 
Mdm2 could play a dominant negative role in cells, WT, BRA, and BRA-DEL Mdm2 
were co-expressed at varying levels with ectopic p53 (Figure 4.3D). These data suggest 
that BRA-DEL can dampen the effects of WT or BRA Mdm2 in degrading p53, perhaps 
by forming mixed Mdm2 oligomers that can target p53 for the 26s proteasome 
differentially (Figure 4.3E). 
 
Cellular consequences in patient cells 
Patient lymphoblastoid cell lines (LCLs) from BRA90250 and BRA9051 were 
compared to lymphocytes from Burkitt Lymphoma patients AG876.  Untreated cells from 
both patients exhibited similar or lower levels of p53 protein, but greater levels of Mdm2 
protein in comparison to control lymphocytes (Figure 4.4A-B). Furthermore, upon 
treatment with Nutlin-3, a small molecule inhibitor that blocks the interaction of Mdm2 
and p53, Mdm2 protein levels are enhanced to a greater extent in patient LCLs than in 
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control cells. (Figure 4.4A). p53 activation by Nutlin-3 treatment confirm that Mdm2 in 
patient cells have p53 degradation activity intact. To investigate other stressors, we also 
treated cells with genotoxic stressors etoposide and doxorubicin and analyzed protein 
expression (Figure 4.4B). Although p53 and Mdm2 level were induced to similar extents 
between control and patient cells, p21 protein was highly induced in BRA90250 and 







Due to the heterozygous nature of the Mdm2 mutation in patients, it is unclear 
which Mdm2 variant is the dominant protein expressed and the primary contributing 
factor to the observed accelerated aging phenotype. In addition, the identified mutation 
in POLD1 driving the patients’ progeria could “hide,” instead of illuminate the role of the 
Mdm2-p53 axis in these patients (Lessel et al., 2015). Intriguingly, the patients had 
altered phenotypes that did not complete recapitulate POLD1-associated progeria 
symptoms previously reported (Pelosini et al., 2014; Shastry et al., 2010). This 
variability could be a result of POLD1 differences or could be attributed to the influences 
of other genes such as Mdm2. Nevertheless, study of the BRA-DEL and BRA Mdm2 
variants reveal novel insights about the function of Mdm2 protein and could potentially 
lead to greater understanding of how the Mdm2-p53 axis is related to aging.  
Understanding the interplay between WT, BRA, and BRA-DEL Mdm2 variants is 
important in determining if there are any dominant-negative effects. Reduced basal 
levels of p53 in patient LCLs suggest that the effects of WT and BRA Mdm2 override 
the effects of BRA-DEL Mdm2 in patient cells. It is also possible that these alternative 
isoforms are expressed at different levels and ratios physiologically, leading to 
increased WT and BRA functional units in the cell. Mixed Mdm2 oligomers with WT and 
BRA functional units enable Mdm2 to retain regulatory function against p53, as Mdm2 
can both repress p53 transcriptional transactivation ability through direct binding and 
ubiquitination (Momand et al., 1992) (Figure 4.4E). Alternatively, BRA-DEL could 
potentially subtly stabilize other Mdm2 variants, which can later form new oligomers that 
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can hyper-degrade p53. Furthermore, the point mutation in the p53-binding domain 
BRA could lead to hyper-degradation of p53, which could account for the subtle 
decrease in p53 protein levels.  Further studies utilizing genome-editing may address 
this complex question. 
It is likely that certain p53 hyper-activated pathways are stressor-dependent and 
play differential roles in driving the aging phenotype (Batchelor et al., 2011; Purvis et al., 
2012). Additionally, Mdm2, p53, and downstream transcriptional target expression may 
be tissue-dependent (Gottlieb et al., 1997).  Therefore, our patient data in LCLs may 
only provide a glimpse of Mdm2 and p53 activity in the human. Data from Nutlin-3, 
cisplatin, and etoposide-treated cells reveal variability in induction of Mdm2 and p21 
proteins. Interestingly, these drugs activate p53 through three different mechanisms, by 
disrupting the interaction of Mdm2 and p53, behaving like an alkylating agent, or directly 
damaging DNA through complexing with topoisomerase II (Dasari et al., 2014; van 
Maanen et al., 1988; Vassilev et al., 2004). Altogether, they imply that although basal 
p53 activity is low in patient cells, exposure to chronic physiological stresses could 
enhance the p53 response. 
Due to our findings suggesting that BRA-DEL is both hyper-stable and unable to 
bind to p53, we believe that the BRA-DEL isoform is primarily responsible for 
contributing to the accelerated aging phenotype. We speculate that the 25 amino acid 
deletion in the p53 domain is crucial to its impaired function. This is consistent with 
three mouse models that feature aberrant Mdm2 regulation of p53 stemming from 
truncation mutations or modifications in the p53 N-terminus. These mice express normal 
p53 protein levels but have constitutively active p53 (Donehower et al., 2009; Moore et 
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al., 2007). Mice bearing one functional copy of wild type p53 and one copy of an N-
terminal truncation of p53 display accelerated aging phenotypes (Maier et al., 2004; 
Tyner et al., 2002). Similar to the effects observed from expression of the BRA-DEL 
variant, these mice have altered interactions with Mdm2, suggesting dysregulation of 
p53 by Mdm2 augmented, abnormal p53 activity. One mutant N-terminal allele 
produced a truncated protein that was able to interact with, stabilize, and facilitate the 
nuclear localization of wild type p53 under basal conditions (Moore et al., 2007). The 
other N-terminal truncation mutation was a naturally occurring p53 isoform, p44 (Maier 
et al., 2004). p44 is a protein that lacks the transactivation domain of p53, as translation 
is initiated from codon 41 of exon 4 in p53. In addition, knock-in T21D and S23D mice 
that have modified p53 N-terminal residues that disrupt its interaction with Mdm2  
leaving it constitutively active also display accelerated aging phenotypes (Liu et al., 
2010). Concurrent deletion of Puma was able to rescue the segmental progeria 
phenotype in these- mice, indicating that apoptosis was the primary driver of aging here. 
 Overall, this investigation of how Mdm2 variants alter wild type p53 activity will 
provide deeper understanding of the mechanism behind aging via the Mdm2-p53 axis, 
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Figure 4.1. Two novel Mdm2 isoforms were identified in patients with segmental 
progeria 
(A) Pedigree of a family with atypical Werner’s Syndrome. (B) Schematic comparing 
WT Mdm2 and two alternative Mdm2 isoforms (BRA and BRA-DEL) generated from a 






Figure 4.2 Mdm2 variants differ in protein levels and abilities to degrade or 
interact with p53 
(A) Degradation assay showing levels of ectopically expressed Mdm2 and p53 protein. 
U2OS cells were transfected with increasing amounts of FLAG-tagged Mdm2 constructs 
(0.5-2 g WT, MUT, BRA, BRA-DEL) and 200 ng HA-tagged p53. Cells were harvested 
at 24h. Cell lysates were used for immunoblotting (IB). A GFP construct was included 
as a transfection and loading control. FLAG, HA, actin, and GFP antibodies were used 
for IB. (B) Degradation assay showing levels of endogenous p53 protein in presence of 
ectopically expressed Mdm2. U2OS cells were transfected with increasing amounts of 
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FLAG-tagged Mdm2 constructs (0.5-2 g WT, MUT, BRA, BRA-DEL) and were 
harvested at 24 h. A GFP construct was included as a transfection and loading control. 
Cell lysates were used for IB. FLAG, actin, anti-p53 (FL-393) and GFP antibodies were 
used for IB.  (C) Levels of Mdm2 protein in a p53-null cell line. H1299 p53-null cells 
were transfected with increasing amounts of FLAG-tagged Mdm2 constructs (0.5-2 g 
WT, MUT, BRA, BRA-DEL) and harvested at 24h. A GFP construct was included as a 
transfection and loading control. Cell lysates were used for IB and probed with FLAG, 
actin, and GFP antibodies. (D) Levels of ectopic p53 protein when WT and MUT Mdm2 
proteins are expressed at similar levels. U2OS cells were transfected with FLAG-tagged 
Mdm2 constructs calibrated to express equivalent levels of Mdm2 variants (2 g WT, 
0.4 g MUT, 2 g BRA, 0.4 g BRA-DEL) along with HA-tagged p53 as indicated. Cells 
were harvested at 24 h. Top panel: Aliquots of transfected cell lysates were subjected to 
IB with the indicated antibodies. Bottom panel: quantitative RT-PCR showing relative 
mRNA levels of Mdm2 in each sample. (E) Shows that ectopic Mdm2 BRA-DEL cannot 
bind to ectopic p53. U2OS cells were transfected with FLAG-tagged Mdm2 constructs 
calibrated to express equivalent levels of Mdm2 variants (2.6 g WT, 0.52 g MUT, 2.6 
g BRA, 0.52 g BRA-DEL) along with HA-tagged p53 as indicated. Cells were 
harvested at 24 h. Aliquots of transfected cell lysates were subjected to IB and probed 
with FLAG, HA, and actin antibodies as input samples. After co-immunoprecipitation 
with anti-FLAG antibody and subsequent IB, Mdm2 and p53 proteins were detected 








Figure 4.3 Mdm2 BRA-DEL variant is stable and can help stabilize p53 
(A) Show p53 and Mdm2 protein turnover. U2OS cells were transfected with FLAG-
tagged N-terminal Mdm2 constructs (2 g Mdm2 WT, MUT, BRA, and BRA-DEL), 200 
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ng HA-tagged p53, and 50 ng GFP. Cells were treated with cycloheximide at T=24 h 
and harvested at the indicated time points (0-90 min). Cell lysates were used for 
immunoblotting (IB) with the FLAG, HA, and GFP antibodies. Western blots were 
quantified using ImageJ software and normalized to GFP. Mdm2 and p53 variant half-
lives were calculated through GraphPad Prism. (B) Levels of ectopically-expressed 
Mdm2 and p53 after proteasome inhibition. U2OS cells were transfected as indicated 
with HA-tagged p53 and FLAG-tagged Mdm2 constructs calibrated to express 
equivalent levels of Mdm2. After 24 h, each set was either untreated or treated with 
MG132 for 4h before harvesting. Protein levels were quantified and normalized using 
ImageJ software. (C) Shows relative ubiquitination of p53 by WT and MUT Mdm2 
proteins. H1299 cells were transfected with constructs expressing N-terminal FLAG-
tagged WT, MUT, BRA, or BRA-DEL Mdm2 (2.6 μg), p53 (260ng), and HA-tagged 
ubiquitin (866 ng), and untagged p53. After 24 h, cells were treated with MG132 (25 μM) 
for 4h before harvesting. Top panel: Aliquots of transfected cell lysates were subjected 
to immunoblotting with the indicated antibodies (Mdm2: FLAG, p53: FL-393, anti-GFP) 
to show input levels of the indicated proteins. Bottom panel: Extracts of cells were 
immunoprecipitated with anti-p53 antibodies (FL-393) and then probed with the anti-p53 
polyclonal antibody (FL-393) to show higher molecular weight ubiquitinated p53 
polypeptides. (D) Mdm2 variants display dominant negative effects. U2OS cells were 
transfected with N-terminal FLAG–tagged Mdm2 constructs WT, MUT, BRA, and BRA-
DEL, HA-tagged p53, and GFP. Cells were harvest 24 h post-transfection, lyses, and 
subjected to immunoblotting with the indicated antibodies. (E) Proposed model of 





Figure 4.4. Effects of stressors in patient LCLs 
(A) AG876 and patient lymphoblastoid cell lines were treated with DMSO, Nutlin-3, and 
cisplatin for 6 hours as indicated. Cells were then harvested and subjected to 
immunoblotting with the indicated antibodies. (B) AG876 and patient lymphoblastoid cell 
lines were treated with DMSO, etoposide, and doxorubicin for 6 hours as indicated. 
Cells were then harvested and subjected to IB with the indicated antibodies (Mdm2 






 BRA90250 BRA90251 Werner Syndrome 
Age at presentation 39 y 10 y >18y 
Sex F M F=M 
Bilateral cataracts No No +* 
Skin changes + + +* 
Pinched nasal 
bridge 
+ + +* 
Short stature + No +* 
Hair changes + No +* 
 
Table 4.1. Clinical features in the patients presented and in Werner syndrome  
Comparison of aging-related characteristics between patients BRA9050, BRA90251, 
and classical Werner syndrome features. Patients have mild aging phenotypes. 
*indicates a cardinal clinical feature for diagnosis of Werner syndrome. 
 


















Perspective and future directions 
 
Perspectives and future directions 
In this dissertation, we have examined how mutations in Mdm2 can contribute to 
human aging conditions. Analyses of two different regions of Mdm2 support the idea 
that proper regulation of p53 by Mdm2 is essential for development, aging, and tumor 
incidence. In chapter two, we identified how a mutation at the extreme C-terminus of 
Mdm2 can abrogate Mdm2 E3 ligase activity but maintain p53-binding function. This 
anti-terminating mutation is found in a patient with a segmental progeria condition. In 
chapter three, we investigated how MdmX could potentially compensate for impaired 
p53 activity. In chapter four, we studied how a heterozygous Mdm2 mutation can lead to 
expression of alternative Mdm2 isoforms that have novel, mixed impacts on p53. 
Commonalities between the E3 ligase-defective MUT and p53 binding-defective BRA-
DEL Mdm2 variants include hyper-stabilization of Mdm2 and p53. Determining how 
mutant Mdm2 exerts p53-dependent and p53-independent functions to stimulate cells to 
acquire aging-associated molecular changes will be crucial to establishing a clear 
mechanistic relationship between the Mdm2-p53 axis and aging 
  As discussed in chapter three, finding the best controls to use and compare 
patient cells to is a challenge. Although genome-editing offers many advantages such 
as endogenous regulation of Mdm2, osteosarcomas may not be the best cells to work 
with. Instead, h-Tert immortalized fibroblasts from patient IV:7 could be an option for 
replacing mutant Mdm2 with wild type Mdm2. Preliminary data show that immortalized 
IV:7 fibroblasts have increased p53 protein levels as compared to immortalized 82:6 
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fibroblasts (Figure 5.1 A). This finding is echoed by immunofluorescence, where IV:7 
p53 is nuclear and overexpressed under basal conditions and enhanced further upon 
p53 induction (Figure 5.1B). However, since these fibroblasts are immortalized by 
telomerase, they may not be susceptible to induced senescence. On the other hand, 
they may be more likely to survive the rigorous pressures of the selection process than 
primary fibroblasts. In addition, reverting the mutant alleles to wild type Mdm2 could 
potentially lead to rescue phenotypes, which could provide clues on pathways and 
factors responsible for aging in patient IV:7. With regards to the mutant Mdm2 
discussed in chapter 4, genome-editing could be used to introduce the single nucleotide 
alteration into cells to gain insight into the expression of physiological ratios of the 
Mdm2 isoforms. Due to its sizable deletion, BRA-DEL Mdm2 has a lower molecular 
weight, which could possibly be separately detected on polyacrylamide gels due to 
altered migration.  
Cells that have “aged” share common prominent molecular hallmarks, including 
genome instability, mitochondrial dysfunction, and senescence, which could be the 
readouts for our assays (Lopez-Otin et al., 2013). Many of these cellular characteristics 
converge through p53 regulation (Vousden et al., 2009). p53 is able to mediate many 
cellular outcomes that trigger aging mechanisms, including autophagy, senescence, 
metabolism, and apoptosis (Kruiswijk et al., 2015). In order to distill which of these 
pathways are driving the accelerated phenotype in patient IV:7, it would be necessary to 
break down each attribute individually. Additionally, treatment with a wide spectrum of 
genotoxic and naturally occurring stressors to induce p53 activation could lead to further 
insights on stress-dependent responses. Mdm2 and MdmX inhibitors such as MEL23 or 
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NSC207895 can also be utilized to elucidate the specific effects of E3 ligase activity on 
p53 outcomes (Herman et al., 2011; Wang et al., 2011).  
Senescence-based assays would work best with intact p16/RB and p19/p53/ARF 
pathways (Kuilman et al., 2010). Initial studies of senescence demonstrate that though 
early passage IV:7 fibroblasts have altered morphology, they are not senescent 
(Figures 3.4 A and B). However, they do enter replicative senescence earlier than 
normal fibroblasts, suggesting that the unusual cell morphology is related to other 
deficiencies (Figures 2.4C and D). We will examine other markers of senescence by 
quantifying the number of senescence-associated heterochromatic foci, probing for p21 
and p16 protein, and examining the expression of p53 senescence targets like PAI-1. 
In order to investigate whether mutant Mdm2 increases proclivity for cell cycle 
arrest, FACS analysis can be employed to obtain a more detailed understanding of the 
basal and stress-induced cell cycle profiles of cells harboring Mdm2 variants. Although 
genome-edited MUT/MUT cells do not exhibit cell cycle differences from Nutlin-3 
treatment, genotoxic stressors result in more differential effects (Figures 3.2E and G). 
Furthermore, preliminary evidence suggest that IV:7 fibroblasts are arrested in G1, 
while IV:7 LCLs are still cycling but undergo more apoptosis (Figures 5.2A and B). This 
could either reflect tissue-specific differences between fibroblasts and transformed 
lymphocytes or the extremely high levels of Mdm2 in IV:7 LCLs. Alternatively, it is 
possible that the observed apoptosis is due to the technical difficulties of maintaining 
suspension cells. Thus, BrdU staining and viability assays can be used to further assess 
the proliferation activity of these cells.  
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To determine metabolic changes, the fluorescent probe 2’,7’-
dichlorodihydrofluoresceine can be used to measure reactive oxygen species (Chen et 
al., 2010).  Expression of p53 target genes involved in metabolism like TIGAR, GLS2, 
GPX1, ALDH4, SCO2 can also be studied. Mitochondrial dysfunction can be studied 
through assays detecting ATP production, respiratory rate, membrane potential, etc . 
In order to determine if cells preferentially shift towards apoptosis under 
genotoxic stress, TUNEL staining, PARP-cleavage, annexin V labeling, and induction of 
caspase-9 through immunoblot analysis are all assays that can be used. In addition, 
RNA levels of p53 targets Bax, Puma, and Noxa can be examined. 
We will also count the number of H2AX foci to quantify if double-strand breaks 
are induced. Stability of the proteins involved in DNA damage repair can also be 
determined via cycloheximide-chase assays, while their activity and localization must 
also be assessed. Genome-maintenance proteins of NBS1 and WRN are of particular 
interest as they have been shown to be binding partners of Mdm2 and p53. Collectively, 
these studies will explore if expression of these Mdm2 variants is sufficient to produce 
the molecular characteristics associated with aging. They may also provide novel 
insights into p53-dependent pathways. 
 
p53-independent roles of Mdm2 
The anti-terminating mutation and natural p53-binding domain deletion in Mdm2 
in progeroid syndrome patients have revealed new functional properties of Mdm2 that 
could contribute to aging. Therefore, it is important to assess the potential p53-
independent roles of the contribution of Mdm2 to aging. Many functions of Mdm2 occur 
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independent of p53 (Ganguli et al., 2003). For example, overexpression of Mdm2 
increased sarcoma development in mice, which is consistent with Mdm2 amplification 
found in human sarcomas (Jones et al., 1998; Leach et al., 1993). Overexpression of 
Mdm2 has also been linked to telomere dysfunction, which can contribute to additional 
chromosome instability (Wong et al., 2003).  Mdm2 can bind to and inhibit NBS1, a 
protein involved in double-strand break repair to promote genome instability (Alt et al., 
2005). Additionally, Mdm2 can inhibit apoptosis by either enhancing anti-apoptotic XIAP 
translation or facilitating the degradation of FOXO3a (Gu et al., 2009; J. Y. Yang et al., 
2008). Therefore, Mdm2 impact on genome instability and continued maintenance of 
unhealthy cells could have aging-related implications in p53-independent settings  
(Lopez-Otin et al., 2013). 
 Dysregulation of other pathways, including the insulin/IGF-1 and mTOR, may 
impact cellular metabolism to promote early aging (Johnson et al., 2013; Zoncu et al., 
2011). Determining how Mdm2 can cross-talk with these pathways will lead to greater 
understanding of Mdm2-driven aging effects. In fact, IGF-1R is a substrate for Mdm2-
mediated ubiquitination and has been linked with regulation of lifespans in mice (Girnita 
et al., 2003; Girnita et al., 2007; Holzenberger et al., 2003; Worrall et al., 2017).  
Initial experiments could overexpress Mdm2 variants in p53-null cell lines (H1299 
or Saos2) to identify how mutant Mdm2 can regulate proteins like p21 and MdmX. In 
order to discover novel interaction partners with our Mdm2 variants, co-
immunoprecipitation/mass spectrometry could be performed. Additionally, ablating or 
fully deleting p53 from patient cells could lead to novel discoveries. Nutlin-3 treatment in 
these cells will lead to alternate changes (e.g. – disrupt Mdm2 binding with E2F1).  
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Global changes in gene expression due to mutant Mdm2 variant expression could be 
unearthed through RNA-seq and validated with qRT-PCR.  
 
Implications for p53 and aging  
p53 has been at the nexus of many human pathologies, including 
neurodegenerative and progeroid disorders (Vousden et al., 2007). The role of p53 in 
tumor suppression is well validated in mouse models (Donehower et al., 2009). 
However, the role of p53 in aging mouse models is much more complicated. 
Accelerated aging mouse models demonstrate that shortened lifespans do not need to 
be dependent on enhanced proclivity for tumor formation (Tables 1.1 and 1.2). Instead, 
chronic stress due to nuclear, genome maintenance, and signaling defects can trigger 
dysregulated p53 activation. However, simple induction of p53 is insufficient in 
producing the phenotype (Garcia-Cao et al., 2002; Matheu et al., 2007; Mendrysa, 
O'Leary, et al., 2006). One caveat is that mice living under laboratory conditions are not 
exposed to everyday physiological stresses. Super p53 and super Arf/p53 mice have 
augmented DNA damage responses, which if chronically stimulated, could potentially 
lead to altered phenotypes. Abstractly, balanced p53 stability is necessary for lifespan 
regulation and tumor resistance (Figure 5.3) We speculate that for p53-mediated aging, 
p53 needs to 1) be stably active due to Mdm2 dysregulation or chronic stress or 2) must 
shift cellular outcomes preferentially towards senescence, apoptosis, or ferroptosis to 
either contribute to the accrual of senescence cells and SASP or deplete the adult stem 
cell pool (Figure 1.4). Natural aging and exposure to external stimuli lead to alterations 
in epigenetic regulation and metabolome (Christensen et al., 2009; Laye et al., 2015). 
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Therefore, we can use different stressors to modulate tissue-specific phenotypes to 
determine if certain conditions preferentially lead to aging-related changes. 
 
Targeting the Mdm2-MdmX circuitry 
The Mdm2/MdmX/p53 axis presents an attractive target for cancer therapeutics, 
particularly those that wish to restore wild type p53 function (Wade et al., 2013) . 
Stapled peptides, small molecule inhibitors, and p53 vaccines have all undergone 
clinical trials to test the efficacy of targeting this pathway. However, there may be 
unanticipated aging consequences due to aberrant p53 activation. Nevertheless, many 
therapeutics seek to disrupt the Mdm2-p53 interaction for p53 activation. Small 
molecule antagonists such as Nutlin-3 and benzodiazepinediones are compounds that 
can induce p53-mediated cell cycle arrest (Grasberger et al., 2005; Vassilev et al., 
2004). RITA is another well-known compound that activates p53 by inducing a p53 
conformational change to disrupt the Mdm2-p53 interaction (Issaeva et al., 2004). In 
addition, both Nutlin-3 and RITA may induce Mdm2-mediated downregulation of IGF-1R 
signaling through ubiquitination, (Di Conza et al., 2012; Worrall et al., 2017). 
However, overexpression of MdmX can dilute the effects of Nutlin-3-dependent 
p53 activation (Hu et al., 2006; Patton et al., 2006). This can potentially be resolved by 
combining MdmX inhibition and Nutlin-3, which can synergistically induce p53-mediated 
apoptosis, indicating that MdmX has compensatory properties (Vaseva et al., 2011). 
Several MdmX antagonists have been identified and could be studied for combinatorial 
effects with Mdm2 inhibition (Popowicz et al., 2010; Reed et al., 2010). In addition, 
stapled peptides have also been shown to be able to activate p53 by blocking both 
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Mdm2 and MdmX (Bernal et al., 2007; Bernal et al., 2010; Y. S. Chang et al., 2013; 
Crunkhorn, 2013). Furthermore, targeting the specific E3 ubiquitin ligase activity of 
Mdm2 and MdmX can also lead to p53 stabilization and activation (Herman et al., 2011; 
Roxburgh et al., 2012; Y. Yang et al., 2005). However, specificity for Mdm2 may be 
difficult to achieve, as other ubiquitin ligases also contain RING domains, leading to off-
target cytotoxicity (Lipkowitz et al., 2011). Interestingly, our data in chapters two and 
three demonstrate the effects of how mutant Mdm2 with impaired E3 ligase activity but 
normal binding activity could partially capitulate the effects of this new class of E3-ligase 
targeting drugs.  
Overall, the balance between Mdm2/MdmX and p53 is crucial for organismal 
homeostasis. Activating p53 can promote tumor-suppressive functions, but at what 
cost? Fortunately, several mouse models have showed that non-aberrant regulation of 
p53 by Mdm2 can restrain p53 activity and promote tumor resistance without the 
damaging lifespan effects (Mendrysa & Perry, 2006). However, future cancer drugs 
targeting the Mdm2-p53 circuitry will need to consider the potential impact of MdmX and 
the long-term consequences of combination therapy. 
 
Therapeutic Implications 
Two general questions frame the search for aging therapeutics: can we curtail 
the aging process and can we reverse the effects of aging? Proof of principle studies 
have demonstrated that aging effects could be reversed in HGPS by a modified 
oligonucleotide that corrects the aberrant splice site in LMNA (Scaffidi et al., 2005). In 
addition, chemical screens are rapidly discovering new inhibitors that can disrupt aging-
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related pathways. For example, a rho-associated protein kinase (ROCK) inhibitor Y-
27362 was discovered to dampen ROS-associated mitochondrial dysfunction in HGPS 
(Kang, Park, Choi, Choi, et al., 2017). 
Other studies have evolved beyond cellular phenotypes and have explored direct 
rejuvenation in mice. Specifically, researchers have attempted to determine whether 
young environments can produce factors or stimuli that can restore youthfulness by 
using heterochronic parabioses to connect the circulatory systems of old and young 
mice (Conboy et al., 2005). In particular, growth differentiation factor 11 (GDF11) 
expression was discovered to reverse skeletal and cardiac aging-related dysfunction in 
mice (Katsimpardi et al., 2014; Loffredo et al., 2013; Sinha et al., 2014). GDF11 is a 
member of the TGF- family of proteins that regulates Hox genes and development that 
appear to decline with age. However, recent studies question these findings and 
suggest that levels of GDF11 increase with age in rats and humans and inhibit muscular 
regeneration (Egerman et al., 2015; Harper et al., 2016). The discrepancies seem to 
stem from antibody reactivity, technical differences, and model organisms (Garber, 
2016). Recently, an HGPS mouse model (Zmpste24-/-) was used to test in vivo GDF11 
therapy and found that although circulating GDF11 declined in the aged mice, daily 
GDF11 intraperitoneal injections cannot prolong accelerated aging mice lifespans 
(Freitas-Rodriguez et al., 2016). Altogether, more research is needed to elucidate the 
role of GDF11 in aging. 
Blood from young mice also have restorative effects on the brain, suggesting that 
it may be possible to improve declined cognitive function that typically associated with 
age. (Castellano et al., 2015; Villeda et al., 2014). Recent advances have demonstrated 
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that tissue inhibitor of mettaloproteinases 2 (TIMP2), a plasma-enriched protein in 
human umbilical cord can restore brain function in mice (Castellano et al., 2017). 
Alternatively, TIMP2 ablation leads to deleterious effects on cognitive function like 
spatial learning and memory. 
Another therapeutic approach explores combating aging through senescence. As 
stated previously, buildup of senescent cells, combined with minimal healthy cell 
turnover and slowed division of healthy cells, is largely thought to drive aging 
phenotypes. Clearance of senescent cells by the immune system is a natural 
mechanism to remove non-proliferating cells from the tissue pool. However, forced 
clearance of senescent cells has been associated with a delay of aging effects (Baker et 
al., 2011). Thus, new drugs are promoting senescent cell clearance to eliminate 
inflammatory SASP responses in aged cells. For example, the small molecule ABT233 
is an anti-apoptotic inhibitor that selectively kills senescent cells, leading to rejuvenated 
hematopoietic stem cells. (J. Chang et al., 2016). Furthermore, a chemical screen was 
employed to identify kinase inhibitors that can rescue senescent phenotypes via two 
readouts: increased cell count and reduced SA-  galactosidase staining (Kang, Park, 
Choi, Kim, et al., 2017). The compound KU-60019 was discovered as an effective 
inhibitor of ATM-driven senescence. Along with reduced phosphorylated ATM, KU-
60119 treatment yielded decreased levels of p53. More recently, a FOXO4-p53 
interfering peptide was used to selectively clear senescent cells from an aged mouse 
(Baar et al., 2017). By perturbing the interaction between FOXO4 and p53, the peptide 
was able to selectively induce p53 nuclear exclusion and p53-dependent apoptosis in 
senescent cells. Intriguingly, the peptide did not raise total p53 protein levels, but did 
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induced accumulation of serine-15 phosphorylated p53. Concordant with diminished 
senescence, a reduction in p21 levels was observed. The resulting clearance of 
senescent cells were able to restore fitness in both naturally aged and XPDTTD/TTD 
accelerated aged mice, effectively demonstrating that p53 could be a promising target 
for aging therapeutics (Baar et al., 2017; de Boer et al., 2002).  
 
Concluding remarks 
 This dissertation aimed to unravel new insights into the Mdm2 protein and how 
the Mdm2-p53 axis is linked to aging. Constitutive dysregulation of the Mdm2-p53 axis 
has now been linked with aging in human progeria pathologies. In addition, MdmX could 
play a major role in facilitating this relationship. Further research is necessary to distill 
which of the many p53 functions is most vital for aging and ultimately reveal the 
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Figure 5.1. Immortalized fibroblasts have elevated p53  
(A) Mdm2, p53, and actin protein levels. IMR90, primary IV:7, and h-Tert immortalized 
fibroblasts were treated with DMSO, Nutlin-3, or daunorubicin for 6 hours before 
harvesting and IB (see chapter 3 for methods). (B) Fluorescence microscopy of 
immortalized 82-6 and immortalized IV:7 fibroblasts. Merge of DAPI (blue), Mdm2 (red), 


















Figure 5.2. Cell cycle profiles of patient cells 
(A) Cell cycle profiles of NHDF, 82-6, and IV:7 patient fibroblasts. FACS was performed 
according to methods described in chapter 3. (B) Cell cycle profiles of Burkitt 
lymphomas AG876 and EW36 (controls) and LCLs from patients BRA90250, 








Figure 5.3. Mouse models connecting lifespan and cancer resistance to p53 
stability  
Abstract relationship comparing how lifespan and cancer resistance is linked to p53 
stability. Low p53 stability (p53+/-) mice are highly tumorigenic and have shortened 
lifespans due to cancer. Mice with normal p53 stability have normal lifespans, peaking 
at super-p53/super-ARF mice that have delayed onset aging. Mice with increased p53 
stability can lead to hyper-activation and accelerated aging phenotypes, but greater 
cancer resistance (dip in lifespan). Finally, mice “possibly with” super-stable p53 due to 
Mdm2 or MdmX deletion leads to embryonic lethal phenotypes. 
